Committee on toxicity of chemicals in food, Consumer products and the environment
Update on the Safety of Ginger Supplement Use in Pregnancy.

Introduction

1. As part of the current programme of work on the maternal diet, the Committee considered the use of dietary supplements during pregnancy. A discussion paper (TOX/2020/51) was presented, reviewing the commonly used dietary supplements during pregnancy. These were supplements that were not officially recommended by the relevant authorities, but which were promoted by anecdotal evidence and unofficial sources as having various purported benefits.

2. The review was confined to herbal dietary supplements which would be regulated under food law and which would not be considered to be traditional herbal medicines which are the responsibility of the Medicines and Healthcare Products Regulatory Agency (MHRA). Following this review, the COT agreed ginger required further investigation, noting that human, animal and in vitro data were available.

3. In May 2021, the Committee considered the potential effects of ginger and ginger supplements during pregnancy and lactation. Paper TOX/2021/26 (attached at Annex A to this paper) reviewed the available data on toxicity to the mother, effects on the development of the fetus or embryo, and possible interactions with drugs as well as data on potential exposure. The minutes discussing this paper are attached at Annex B to this paper.

4. Overall, it was concluded that there were limited data. The human data presented were not strongly indicative of any toxicological concern but there were some indications of possible adverse effects and a lot of uncertainties. Ginger did not appear to be systemically toxic but did appear to have reprotoxic effects at high supplemental doses.

5. The best estimate of a point of departure from available animal studies was considered to be around 50-100 mg/kg based on the reproductive studies. The Committee suggested looking at the animal data in closer detail to determine the point of departure (No Observed Adverse Effect Level- NOAEL), followed by calculating the potential exposure to supplements to determine whether there was
cause for concern. The current paper provides further information with respect to animal studies, contaminants and exposure to ginger supplements.

6. Based on the Committee’s suggestions, a further literature search was performed to further inform the available database on the points raised by the Committee. The focus of the search was primarily centred on the effect of ginger on prostaglandins, reproductive and developmental toxicity and the possible contaminants present in ginger.

Background

7. Ginger (*Zingiber officinale*) is a flowering tropical plant originating in Southeast Asia and grown in warm climates including China, India, Africa and the Caribbean. The rhizome (underground stem) of the ginger plant is commonly used as a spice and flavouring in many countries around the world and is increasingly growing in popularity as a natural remedy due to its purported immune system-boosting properties and also for motion sickness and post-operative nausea and vomiting. The ginger rhizome contains two main classes of constituents: the essential oils responsible for the aroma, and the main bioactive components - gingerols and shogaols.

8. There are currently no health-based guidance values (HBGV) with respect to ginger or its main components. Exposure to ginger was considered based on information found on supplement and tincture composition and background diet, but the variability of available supplements means exposure will also vary.

Uses

9. As mentioned in the paper TOX/2021/26, ginger is commonly consumed in fresh root form, dried root powder, capsule (encapsulated dried powder) form, liquid extract, preserved in syrup or sugar and as a tea. Ginger is a common traditional treatment for prophylaxis of motion sickness, Digestive disorders, upset stomach and nausea. In pregnancy it is most used in the treatment of pregnancy-related nausea (NHS). It has also been used as a dietary supplement and a traditional remedy in many cultures. Ginger is included in the official pharmacopoeias of several western countries.

Health based guidance values

10. There are currently no HBGVs with respect to ginger use during pregnancy and no consensus on the safe dosage of ginger. The UK Teratology Information Service (UKTIS) have concluded that while exposure to ginger would not usually be regarded as grounds for termination or additional monitoring during pregnancy, other
factors could affect the overall risk outcome, and this is something that would take place on an individual basis (UKTIS, 2017).

Main outcomes of the discussions on TOX/2021/26

11. Paper TOX/2021/26 reviewed the available studies on cytotoxicity, mutagenicity, acute, reproductive and developmental toxicity, lactation and possible drug interactions as well as data on potential exposure in pregnancy, covering both animal and human studies.

12. The Members noted that the results of studies in pregnant women were varied and the overall findings inconclusive (see minutes in Annex B). There were some reports of an increased incidence in spontaneous abortion, however overall, these studies were contradictory. There were no reported effects of defects post-partum following exposure to ginger. Members had questioned what the mode of action for the purported beneficial effects of ginger on nausea might be and it was suggested that ginger might act to decrease prostaglandin levels, which were linked to nausea. The COT concluded further studies would be needed to determine the role of increased prostaglandin levels in the early termination of pregnancy.

13. Human data showed possible interactions with medicines. A point of departure for this effect was difficult to determine, however, an estimated level of 100 mg/kg was suggested from animal studies. It was noted that some of the toxicity observed varied according to the nature of extraction solvent - organic solvent extracts exhibited more toxicity than aqueous extracts, which presumably indicates extraction of differentially toxic compounds. Hence, studies of individual extracts might not give the whole picture of the uncertainties involved.

14. The animal studies of reproductive toxicity considered in TOX/2021/26 reported a number of findings, including, reduced maternal weight gain, increased fetus weight, increased serum testosterone level in F1 generation males and an increase in embryonic loss.

15. Ginger was reported to have antiplatelet activity, with some studies reporting effects in animals at doses of 500 mg/kg bw. This further highlighted the need to differentiate exposure from the normal diet to that from supplements.

16. The best estimate of a point of departure from available animal studies was around 50-100 mg/kg based on the reproductive studies. The Committee suggested looking at the animal data in closer detail to determine the point of departure (NOAEL), followed by calculating the potential exposure.

17. The Committee considered the animal studies to be inconclusive, however, a change in testosterone levels was noted in F1 generation male rats exposed to an alcoholic extract of ginger (Annex A, paragraph 29). Members noted there appeared
to be an association with haemorrhagic effects following exposure to ginger, however the results of these studies were not conclusive.

**Update to the literature since the initial review**

18. As noted above, a further literature search was performed to further inform the available database on the points raised by the Committee, covering the effects on prostaglandins, reproductive and developmental toxicity and possible contaminants. Described below are those relevant papers identified in an updated literature search focusing primarily on the effect of ginger on prostaglandins, reproductive and developmental toxicity and possible contaminants to ginger.

**Effect on Prostaglandins**

19. Ginger extracts, along with many gingerols and shogaols have been shown to suppress prostaglandin synthesis *in vitro*, through inhibition of cyclooxygenase (Jolad et al. 2005; Pan et al. 2008; Dugasani et al. 2010).

20. Lantz *et al.* investigated the anti-inflammatory effect of ginger extracts and the principal components thereof (6-, 8-, 10-gingerols and 6-, 8-, 10-shogaols) in an *in vitro* model. U937 cells, differentiated and exposed to lipopolysaccharide (LPS) from *Escherichia coli* (1 mg/ml). Extracts containing predominantly gingerols were found not to be cytotoxic, while shogaols were found to be cytotoxic at concentrations above 20 µg/ml (2007).

21. Jolad *et al.* also demonstrated the inhibitory effect of gingerols on LPS-induced PGE2 production in HL-60 cells stimulated with 1 µg/ml of LPS (2004). None of the compounds tested were shown to be cytotoxic.

**Reproductive and developmental toxicity**

22. To date, the number of studies on the safety of the use of ginger supplements during pregnancy is limited. The ginger component 6-gingerol, was highlighted to affect some essential embryonic developmental processes, such as the disruption of angiogenesis. Kim *et al.*, demonstrated the ability of 6-gingerol to inhibit proliferation and tube formation of primary cultured human endothelial cells in rat aorta by down regulation of cyclidin D and the ability to inhibit tumour growth in mice through its anti-angiogenic activity (2005).
In vitro studies

23. Mohammed et al investigated the effects of herbal extracts, including ginger and 6-gingerol, on chick embryonic heart micromass and mouse D3 embryonic stem cell systems (ESD3) (2016). The team observed that the use of ginger herbal remedies in the first trimester of pregnancy may affect foetal development. However, 6-gingerol-treated primary embryonic chick cardiomyocytes showed no significant changes in contractile and cellular activity or changes in total protein content in comparison to the control.

24. At concentrations of 0.75–6 µM, 6-gingerol treated primary embryonic chick cardiomyocytes exhibited no significant changes in contractile activity, cellular activity or changes in total protein content in comparison to the control. At concentrations of 12.5–50 µM, inhibition in contractile activity was observed at 48h. All high 6-gingerol concentrations, 12.5–100 µM, tested in micromass, significantly altered both the cellular activity and protein content in a dose-dependent manner.

25. The same concentrations of 6-gingerol were used to treat the ESD3, which showed a significant decrease in cardiomyocyte differentiation for all tested concentrations except 0.75 µM. The cellular activity and protein content of stem cell-derived cardiomyocytes also exhibited a significant decrease with increased 6-gingerol concentration exposure. The 6 µM dose showed almost no differentiation in the morphological score on days 10 and 11, which was considered an anomaly. However, a small amount of differentiation was observed on day 12.

In vivo studies

26. Shalaby and Hamowieh investigated fertility, serum testosterone and acute toxicity of ginger in rats (2010). 120 male Sprague Dawley rats, separated into groups of 10, were orally administered either water (prepared using 100 g dry ginger roots soaked in 500 ml water or 500 ml methyl alcohol 90%) or methanolic extracts in graded doses ranging from 5 to 17.5 g/kg bw (gavage doses were not specified). Following dosing, the number of dead mice in each group after 48 hours of observation were recorded. The oral Lethal Doses (LD50) of the methanolic and water extracts were calculated to be 10.25 and 11.75 g/kg bw respectively. No symptoms of toxicity were observed at does up to 5 g/kg bw. Both extracts increased fertility index, sexual organ weight, and sperm motility and count after 65 consecutive days (see below).

27. To investigate the effect if ginger extracts on serum testosterone levels, male rats, rendered diabetic by subcutaneous injection of 120 mg/kg bw alloxan for 3 days, were administered methanolic extracts of ginger for 65 days at doses of 100 and 200 mg/kg bw/d. Testosterone levels increased to 4.08 ± 0.10 and 7.13 ± 0.14 ng/dL (both significant at $P < 0.001$) compared to the diabetic control group who had levels of 3.30 ± 0.03 ng/dL. Serum testosterone levels also increased in rats given water extracts (150 and 300 mg/kg bw) were determined to be 4.06 ± 0.03 and 5.04
± 0.08 ng/dL (both significant at $P < 0.001$ when compared to the diabetic control group) respectively.

28. The team also investigated fertility with regards to fertility index (for each male this was calculated as percentage of number of females that become pregnant in relation to number of mated females) and spermatogenesis. Rats were orally administered methanolic extracts at doses of 100 and 200 mg/kg bw for 65 consecutive days and water extracts at doses of 150 and 300 mg/kg bw and compared to a diabetic control group.

29. Histopathological examination of the testes of diabetic rats showed mild to moderate degenerative changes of spermatogenic cells, diffuse oedema and incomplete arrest of spermatogenesis. The testes of rats orally administered 300 mg/kg bw of water extract of ginger roots showed mild degeneration of spermatogenic cells and slight oedema of interstitial cells. The testes of rats receiving orally 200 mg/kg bw of methanolic extract of ginger roots showed nearly normal seminiferous tubules, showing fewer signs of degradation, suggesting a LOAEL of 200 mg/kg bw/day for the methanolic extract. The team concluded that the results suggest the intake of ginger root as a drink may be useful for diabetic patients suffering from sexual impotency.

30. The above study has been included for completeness and as any general mechanisms may be more widely relevant: This is consistent with the findings of Hosseini et al (2015) – see paragraph 29, Annex B.

31. No additional reproductive studies were identified. Therefore any point of departure for ginger would need to be based on the animal studies discussed in TOX/2021/26 and reproduced below.

Reproductive and developmental toxicity has also been investigated in rat studies. In a study by Wilkinson (2000), three groups of pregnant Sprague-Dawley rats were administered either a control (unspecified), or 20 g/L or 50 g/L ginger tea - prepared by the infusion of grated ginger in water via their drinking water - during days 6 to 15. No further details were provided regarding specific compounds of interest. While no maternal toxicity was observed, embryonic loss in the treated groups was found to be double that of the controls. Exposed foetuses were found to be significantly heavier than controls and showed no gross structural malformations. The results of this study suggest that in utero exposure to ginger tea results in early embryonic loss and increased growth in surviving foetuses.

Hosseini et al. investigated the effect of ethanolic ginger extract on serum testosterone, LH and FSH as well effect on spermatogenic cell lines in male mature offspring rats (2015, abstract only). In this study, 72 female rats, sorted into 9 groups were orally administered of alcoholic extract of ginger at doses of 50, 100 and 200 mg/kg bw, during their neonatal and perinatal
periods versus saline as a control. Following puberty, LH, FSH, cell numbers of Sertoli, spermatogonia, spermatocyte and spermatids were counted in 8 male rat offspring from each group. Ginger was found to significantly increase testosterone levels and the number of spermatogenic cells and at doses of 100 and 200 mg/kg bw, alcoholic extract of Ginger significantly reduced the FSH and LH compared to control groups. The authors concluded that “the oral consumption of Ginger during pregnancy and lactation dose-dependently increase the level of testosterone and the number of spermatogenic cells.”

The teratogenicity of EV.EXT 33, a patented Zingiber officinale extract (comprising 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, and 8-shogaol, which made up 1.9 w/w of the extract) was investigated in Wistar rats, (Weidner & Sigwart, 2001). The extracts were administered orally by gastric intubation at concentrations of 100, 333 and 1000 mg/kg, to three groups of pregnant rats from days 6 to 15 of gestation. Their bodyweight, food and water monitored during the treatment period. The study concluded that treatment with EV.EXT 33 during the period of organogenesis resulted in neither maternal nor developmental toxicity at daily doses of up to 1000 mg/kg bw.

Dissabandara & Chandrasekara (2007) also examined the effect of powdered ginger extract administered prenatally on the postnatal development of rats. A period of administration of the dry powdered extract orally at doses of 500 mg/kg/day or 1000 mg/kg/day (control not specified) during days 5 to 15 of gestation resulted in a lower intake of food and water and lower weight gain in the ginger treated group, suggesting that maternal administration of ginger during mid pregnancy resulted in reduced maternal weight gain and increased embryonic loss without affecting the postnatal growth and physical maturation of the surviving offspring.

ElMazoudy and Attia (2018) investigated the effect of powdered dried ginger root on the oestrus cycle and implantation in female mice. ICR mice, orally dosed at 250, 500, 1000, or 2000 mg/kg bw/d aqueous ginger extract. These were investigated in four different experiments: the main study of outcomes (treatment for 90 days and throughout mating and gestation), a 35-day treatment study evaluating effects on the oestrous cycle. The third and fourth intended antifertility and abortifacient loss (20 days treatment). In the main study, the dams were sacrificed on gestation day 20. One mortality was recorded in the 100mg/kg bw/d group on gestation day 18 and two mortalities in the 2000 mg/kg bw/d group at day 16. There was also a significant reduction in body weight change in these two dose groups compared to the control group; however, food consumption was comparable.

In the study investigating the oestrus cycle, a significant reduction in the numbers of oestrus cycles was observed at the highest dose group, with the
length of the oestrus cycle in this group being significantly prolonged (10.05 ±0.8) days compared with (4.99 ± 0.5) days recurrent and successive oestrous cycles in control mice. At the highest dose level, the length oestrous cycle was prolonged with a significant decrease in the duration of diestrous-metestrus (luteal) phase and prolonged proestrus-estrus (ovulatory) phase. In the study investigating pre-implantation loss, a significant decrease in the number of corpora lutea was observed at the highest dose group. Implantation failure was also increased by 36% compared to the control group and pre-implantation loss at this dose group was also 16.59% higher than the control group. The authors considered that this may reflect a dose-depend antifertility (anti-implantation) effect.

Regarding fertility and developmental outcomes, the female copulation index was significantly reduced at 2000 and 1000 mg/kg bw/d groups, whereas the female pregnancy index was significantly decreased only at the highest dose. The number of implantation sites and live fetuses in the 2000 mg/kg bw/d group were lower than the other treated and control groups. An increase in fetal resorption and post implantation loss was also seen at the highest dose group. There was no evidence of fetal malformations however growth retardation, reduced pup weight and delay in the crown-rump length was observed at this dose group as well. Finally, changes in ovarian histopathology were observed at 2000 mg/kg bw/d, following 90 days of treatment. Ovarian follicle atresia was observed. The atretic follicles contained cell debris and there was haemorrhage in the antral cavity.

Additionally, degenerated primordial follicles with pyknotic nuclei forming polycystic ovaries were noted. Deteriorated follicles were observed as a detaching of layers of granulosa cells from the basal membrane by dilation of zona pellucida and with evidence of apoptosis in damaged ova follicular nuclei were non-visible. The authors considered the above observations as evidence that ginger possesses anti-ovulation properties. Overall, the authors concluded that ginger impairs the normal growth of corpus luteum because of progesterone insufficiency during early pregnancy and that the results suggested that ginger can disrupt the oestrous cycle and blastocyst implantation without teratogenesis. They considered the highest NOAEL to be 500 mg/kg bw.

32. The above papers have been attached at Annex C

Contaminants

33. Differences in cultivation conditions and extraction methods could lead to possible sources of contamination from microbiology, pesticides, heavy metals and residual solvents, exposure to which can lead to hepatic and renal failure and
exacerbation of pre-existing conditions and diseases. Studies investigating contamination in ginger are limited, however of the few available the main sources of contamination reported are heavy metals and mycotoxins.

Heavy metals

34. Studies indicate heavy metal content varies according to cultivation site (Wagesho & Chandravanshi, 2015; Goroya et al, 2019). All studies also indicate that the extraction method also influences heavy metal concentration in the extracts.

35. A study by Kilic & Soylak investigated the presence of trace element contaminants in a selection of herbal teas, including ginger purchased from a selection of (unspecified) herbalists in Turkey. Ginger teas prepared by infusion were found to contain metals including arsenic (8.1 µg/L), barium (14 µg/L), cobalt (3 µg/L), chromium (6 µg/L), copper (51 µg/L), nickel (17 µg/L) and zinc (163 µg/L) (2019). Samples prepared by microwave digestion were also found to contain cadmium, lead and selenium but showed no traces of chromium or vanadium.

36. Getaneh et al investigated the concentrations of heavy metals Cd, Cr, Cu, Fe, Ni, Pb and Zn in ginger purchased from markets in the East Dembia, West Dembia and Gondar Zuria districts, and the associated health risks associated with consumption. The three regions are the main ginger producing areas of the western Amhara Region in Ethiopia. Ginger samples were prepared by digestion with a mixture of HNO₃ and HClO₄ at 200 ºC for 2:00 hours and analysed by flame atomic absorption spectrometry (FAAS). Whilst Pb was not detected, mean concentrations ranged between 4.63 to 5.43 mg/kg for Cd, 2.17 to 4.44 mg/kg for Cr, 62.52 to 65.14 mg/kg for Cu, 77.71 to 81.12 mg/kg for Fe, 6.49–7.58 mg/kg for Ni and 16.74–19.31 mg/kg for Zn. For all samples, the hazard index values for all metals (HI, calculated as the sum of the Target hazardous quotient (THQ)) was found to be slightly over 1, indicating a potential health risk. Element concentrations appeared to vary with sampling site.

37. Xu et al (2020) investigated the effect of mercury on ginger growth, the use of silicon to reduce the mercury toxicity and whether mercury contamination poses a potential significant threat to human health. 0.2 g dried ginger sample was prepared by pressure tank digestion and analysed using cold vapor atomic absorption spectrometry (CVAAS). The team demonstrated that high soil mercury levels inhibited growth, yield and quality of ginger rhizome. Results also showed that the newly grown ginger had a lower levels of mercury residue and accumulation occurred at the root first which is related to the growth cycle of ginger and its absorption and enrichment time of mercury in the environment.
Mycotoxins

38. Mycotoxins present another possible source of contamination. Ginger can be exposed to contamination during harvesting, storage and handling. Whilst information on mycotoxin contamination in ginger is limited, ginger has been demonstrated to be particularly exposed to aflatoxins and ochratoxin A (OTA). As a result, the European Commission set maximum levels of 5 µg/kg for aflatoxin B₁ (AFB₁), 10 µg/kg for all aflatoxins (sum of AFB₁, AFB₂, AFG₁, and AFG₂) and 15 µg/kg for OTA.

39. Altyn and Twarużek reviewed mycotoxin occurrence in the principal herbal components of liquorice, chamomile, mint, ginseng, milk thistle, and ginger and compared them to current regulations (2020). Studies where ginger samples were tested were found to be contaminated with mycotoxins (total aflatoxins, AFB₁, OTA, zearalenone, deoxynivalenol, citrinin) but at levels below the thresholds of 5 µg/kg for AFB₁, (10 µg/kg for all aflatoxins), 15 µg/kg for OTA, 200-750 µg/kg for deoxynivalenol and 20-100 µg/kg for Zearalenone (value in cereal-based foodstuffs). However, Tosun & Arslan conducted a study where spices tested, for AFB₁, including ginger, exceeded the EU acceptable level (2013). Four samples of ginger were tested, of which, three were found to be positive for AFB₁. AFB₁ concentration was found to be in the range of 3.8-23.1 µg/kg (mean 16.5 µg/kg)

40. Wen et al., tested a range of 30 samples of ginger including: fresh ginger, mouldy ginger, dried ginger peels, ginger power and ginger tea bags (2014). OTA was detected in the mouldy fresh ginger and two of three ginger samples at concentrations ranging between 0.31-5.17 µg/kg. AFB₁ was detected in ginger tea bag and ginger black tea bag sample at a concentration of 0.31-1.38 µg/kg.

41. The mycotoxin levels detected in ginger also appear to be dependent on time of cultivation. Omotayo et al compared aflatoxin levels in ginger extracts from ginger cultivated at different times of year in Mahikeng - the capital city of the north west province of South Africa (2019). Ginger samples were collected in summer and winter, (50 per season, in increments of 10 every 2 weeks). Total aflatoxins and ochratoxin A were detected in a range of samples cultivated in both summer and winter by ELISA. Aflatoxin concentrations ranged between 6.4 – 411.1 µg/kg in summer and 3.625 – 105.7 µg/kg in winter. Ochratoxin A concentration ranged between 0.0960–3.395 µg/kg for the ginger collected in winter, and between 0.0968–3.309 µg/kg for those collected in summer. It is unclear whether the samples were stored prior to analysis.

42. Lippolis et al. observed the incidence of aflatoxins and OTA contamination was higher in ginger grown in Nigeria during the rainy season (81% and 77%, respectively) than the dry season (46% and 37%, respectively). Average levels of AFs and OTA in positive samples were 3.13 and 5.10 µg/kg in the rainy season.
(range 0.11-9.52 µg/kg and 0.20-9.00 µg/kg) and 1.18 and 2.76 µg/kg (range 0.20-3.57 µg/kg and 0.17-12.02 µg/kg) in the dry season, respectively (2017).

Exposure

43. Previously, TOX/2021/26 demonstrated that the potential risks arising from exposure to ginger from food can be considered low compared to exposure from supplements, which are available at much higher doses due to the concentrated nature of supplements and shots.

44. The Committee highlighted that assumptions would have to be made on how many products, such as ginger shots, were consumed per day. The Committee noted that, as it is commonly understood that ginger suppresses morning sickness, it could not be ruled out that pregnant women would be using the supplements in this way. Diet plus supplement exposure would need to be considered, as well as diet plus shots depending on the exposure period of concern.

Consumption of ginger from food sources

The FSA Exposure team have sourced information on Ginger intake in women of childbearing age from food. Due to the limited information on consumption amounts of supplements and drinks in pregnant women, exposure was estimated based on the compositional information and usage information in widely available supplements and information on concentrated drinks. Full details of the ginger sources are given in Annex D.

Table 1: Estimated ginger consumption from a variety of sources in women aged 16 – 49 years old

<table>
<thead>
<tr>
<th></th>
<th>Range of daily recommended consumption</th>
<th>Acute consumption*</th>
<th>Chronic consumption*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>97.5th percentile</td>
<td>Mean</td>
</tr>
<tr>
<td></td>
<td>g/day</td>
<td>g/kg bw/day</td>
<td>g/day</td>
</tr>
<tr>
<td>Food(^a)</td>
<td>-</td>
<td>-</td>
<td>1.7</td>
</tr>
<tr>
<td>Drinks(^{b\text{1,}\text{b}}) (including tea and shots)</td>
<td>0.5-32.5</td>
<td>0.0071-0.46</td>
<td>-</td>
</tr>
<tr>
<td>Supplements(^c)</td>
<td>0.010-24</td>
<td>0.00014-0.34</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^{1}\)This assumes only one serving is consumed per day
a Data obtained from the National Diet and Nutrition surveys years 1-8 calculated from women of a childbearing age (16-49 years) (Bates et al., 2014; 2016; Roberts et al., 2018).
b Data obtained online from retailers, see Appendix 1 for further details.
c Data obtained online from retailers, see Appendix 1 for further details.
*Rounded to 2 significant figures.

45. Table 1 provides consumption estimates for women of childbearing age - (16-49 years) 1 from years 1 – 8 of the NDNS survey (Bates et al., 2014; 2016; Roberts et al., 2018). The NDNS (Bates et al., 2014; 2016; Roberts et al., 2018) does not provide data for pregnant or lactating women so while data is based on women of childbearing age, this data may not necessarily be representative of the maternal diet. The food group used for the consumption assessment consisted of all foods within the NDNS database which contained ginger (raw, powdered etc) except for alcoholic beverages. Mean acute ginger consumption from the diet of women aged 16-49 years old was 0.026 g/kg bw/day, and at a 97.5th percentile consumption was 0.16 g/kg bw/day. The corresponding mean and 97.5th percentile chronic consumption was 0.0083 and 0.058 g/kg bw/day. The upper value of the range of consumption from drinks and supplements was over double those estimated from 97.5th percentile acute consumption from food.

46. As the NDNS does not provide data for pregnant women, there would be uncertainty as to whether the data in Table 1 are an accurate reflection of consumption during pregnancy. This uncertainty also extends to data presented for drinks and supplements, as the pattern of consumption during pregnancy to alleviate symptoms of sickness is unknown.

Summary and discussion

47. Previously in TOX/2021/26, chronic consumption of ginger in women of childbearing age from food was considered. Table 1 shows the mean chronic consumption of ginger from the diet of women aged 16-49 years old was determined to be 0.0083 g/kg bw/day, and at a 97.5th percentile consumption was 0.058 g/kg bw/day. Mean acute ginger consumption from the diet of women aged 16-49 years old was 0.026 g/kg bw/day, and at a 97.5th percentile consumption was 0.16 g/kg bw/day.

48. A high-level consumer of ginger could result in an estimated acute consumption level of 11 g ginger per day from food (Table 1). Chronic consumption at the 97.5 percentile level would result in intakes of 3.4 g/day. Ginger intakes from supplements can lead to an estimated daily consumption ranging from 0.00014 to 0.34 g/kg bw. Consumption of ginger from concentrated shots by far contributes the largest amounts of ginger, with estimated amounts of ginger being as high as 27.5 g in a 110 ml shot (Appendix 1, Table 2). Assuming one concentrated shot per day is consumed, a combination of food, supplements and shots could lead to ginger
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

intakes of over 40 g per day. However, factors including preparation method of food, and ginger extract type and method of extraction will determine actual amounts of gingerols and shogaols the consumer is exposed to.

49. There is a high uncertainty regarding the risk of consuming ginger drinks and particularly, concentrated ginger ‘shots’, which can contain as much as 27 g of raw, pressed ginger root per serving. Some marketed supplements provide limited composition information, which adds further uncertainty of the exact exposure to the various components of ginger. It is considered that in addition to exposure from consumption of food and supplements, women may consume more than one concentrated shot per day. The food consumption data provided are specifically for women of childbearing age. For supplements, some of the recommendations are specifically for pregnant women and some of the data provided are for people in general therefore, it may be difficult to make direct comparisons.

50. It is also not possible to tell if supplement consumption would be on a short-term basis (over the course of the pregnancy), or on a longer basis.

51. The studies of reproductive toxicity considered in TOX/2021/26 reported a number of findings, including, reduced maternal weight gain, increased fetus weight, increased serum testosterone level in F1 generation males and an increase in embryonic loss. Members noted that the point of departure appeared to be in the range 50-100 mg/kg bw.

52. In the new literature considered in this paper, ginger extracts did not show acute toxicity at doses of up to 5 g/kg, which is in agreement with previous toxicity studies detailed in TOX/2021/26. Extracts of ginger were shown to increase serum testosterone levels, relative testes weight, sperm quality and ameliorate histopathological lesions compared to diabetic controls, which is consistent with previous findings.

53. Various studies have reported contamination in ginger, the main contaminants being heavy metals and mycotoxins. Levels of both heavy metals and mycotoxins observed were shown to be dependent on factors including location and time of cultivation. Storage may also affect contaminant levels however, this was not fully demonstrated in the studies found. It is presumed that extraction method would also affect levels of contaminants detected in ginger extracts.

Conclusions

54. Ginger (Zingiber officinale) is the rhizome of the ginger plant, originating from in Southeast Asia. Ginger is commonly used as a spice and flavouring in many countries around the world and is increasingly growing in popularity as a natural
remedy due to its purported immune system-boosting properties and also for motion sickness and post-operative nausea and vomiting.

55. Ginger supplements are regarded as a “safe” by women looking for a natural alternative for the relief of morning sickness. Some adverse effects have been reported however, few specific safety studies have been carried out in this area.

56. The lack of safety and toxicological information available on ginger use in pregnancy make it difficult to fully characterise the risks. Based on new data, there was no evidence of acute toxicity from ginger extracts at doses of up to 5 g/kg, which is in agreement with previous toxicity studies detailed in TOX/2021/26. In females, findings such as reduced maternal weight gain, a reduced number of oestrous cycles and ovarian follicle atresia at doses of 2000 mg/kg bw/d. The point of departure for other reproductive effects may be in the range 50-100 mg/kg bw. Ginger extracts are also demonstrated to affect testosterone and sexual organs in male animals, however further studies would still be necessary to determine the full extent.

57. In addition to carbohydrates, protein and sugars etc, ginger contains multiple active chemical components (gingerols, shogaols etc). Cultivation in different regions, at different times of year, temperatures, and humidity influences the amount of the main chemical components of ginger. The levels at which these components occur in supplements vary according to the extraction method employed, resulting in a large variation in the compositions seen. Many of the supplements reviewed do not offer information on extraction methods used, or chemical composition of the extracts, making a direct comparison of the extracts difficult. This also adds to the uncertainties associated with the assessment.

Questions for the committee:

Members are asked to comment on:

a) Based on the newly available information, is the Committee able to identify a point of departure to be used in the risk assessment of ginger?

b) Is it possible to establish a point of departure based on the studies considered in the previous paper?

c) The possibility of contamination of ginger

d) Any further comments on this paper.

Secretariat

October 2021
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

Annexes to this paper

Annex A: COT paper on the safety of ginger and ginger supplements may have during pregnancy and lactation

Annex B: Final COT minutes - May 2021

Annex C: Papers on reproductive toxicity

Annex D: Ginger content in ginger drinks, shots and supplements
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

References


The Committee on Toxicity of Chemicals in Food, Consumer Products and the environment (COT) (2020). Available at: COT Contribution to SACN review of nutrition and maternal health: proposed scope of work and timetable.


The Committee on Toxicity of Chemicals in Food, Consumer Products and the environment (COT) (2021). Available at: The potential effects that ginger and ginger supplements may have during pregnancy and lactation.


Getaneh A, Guadie A, Tefera M (2021). Levels of heavy metals in ginger (Zingiber officinale Roscoe) from selected districts of Central Gondar Zone, Ethiopia and


NHS (2021) Available at: Vomiting and morning sickness.


The Scientific Advisory Committee on Nutrition (SACN) (2011) The influence of maternal, fetal and child nutrition on the development of chronic disease later in life
The Scientific Advisory Committee on Nutrition (SACN) (2018) Feeding in the first year of life


This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMET</td>
<td>Absorption, distribution, metabolism, excretion, and toxicity</td>
</tr>
<tr>
<td>ADI</td>
<td>Acceptable daily intake</td>
</tr>
<tr>
<td>ADP</td>
<td>Adenosine diphosphate</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine Aminotransferase</td>
</tr>
<tr>
<td>AF</td>
<td>Aflatoxin</td>
</tr>
<tr>
<td>AFB&lt;sub&gt;1&lt;/sub&gt;</td>
<td>Aflatoxin B&lt;sub&gt;1&lt;/sub&gt;</td>
</tr>
<tr>
<td>AFB&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Aflatoxin B&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td>AFG&lt;sub&gt;1&lt;/sub&gt;</td>
<td>Aflatoxin G&lt;sub&gt;1&lt;/sub&gt;</td>
</tr>
<tr>
<td>AFG&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Aflatoxin G&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td>AM</td>
<td>Acetoxyethylmethyl</td>
</tr>
<tr>
<td>ASA</td>
<td>Acetylsalicylic acid</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate Aminotransferase</td>
</tr>
<tr>
<td>BGL</td>
<td>Blood glucose level</td>
</tr>
<tr>
<td>CCB</td>
<td>Ca&lt;sup&gt;2+&lt;/sup&gt; channel-blocking</td>
</tr>
<tr>
<td>COT</td>
<td>Committee on Toxicity</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>EFSA</td>
<td>Scientific Committee on Food and the European Food Safety Authority</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>FAAS</td>
<td>Flame atomic absorption spectrometry</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCE</td>
<td>Ginger crude extract</td>
</tr>
<tr>
<td>GRAS</td>
<td>Generally recognised as safe</td>
</tr>
<tr>
<td>HBGV</td>
<td>Health-based guidance values</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>μg/kg bw/d</td>
<td>Micrograms per kilogram bodyweight per day</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>mg/kg bw/d</td>
<td>Milligrams per kilogram bodyweight per day</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare Products Regulatory Agency</td>
</tr>
<tr>
<td>NDNS</td>
<td>The National Diet and Nutrition Survey</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>OTA</td>
<td>Ochratoxin A</td>
</tr>
<tr>
<td>PE</td>
<td>Phenylephrine</td>
</tr>
<tr>
<td>PGE&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Prostaglandin-E&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td>PTT</td>
<td>Partial thromboplastin time</td>
</tr>
<tr>
<td>SACN</td>
<td>Scientific Advisory Committee on Nutrition</td>
</tr>
<tr>
<td>STZ</td>
<td>Streptozotocin</td>
</tr>
<tr>
<td>TBX&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Thromboxane-B&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td>UKTIS</td>
<td>UK Teratology Information Service</td>
</tr>
</tbody>
</table>
Search Terms

The following terms were input into PubMed and the relevant papers and references found therein were cited in this paper:

Ginger and
extract
extract and toxicity
supplement
pregnancy
cytochrome
safety
EFSA
Gingerols
prostaglandins
contaminant
heavy metals
follicular failure
Committee on toxicity of chemicals in food, Consumer products and the environment

The potential effects that ginger and ginger supplements may have during pregnancy and lactation.

Background

1. The Scientific Advisory Committee on Nutrition (SACN) last considered maternal diet and nutrition in relation to offspring health in its reports on ‘The influence of maternal, fetal and child nutrition on the development of chronic disease in later life’ (SACN, 2011a) and on ‘Feeding in the first year of life’ (SACN, 2018). In the latter report, the impact of breastfeeding on maternal health was also considered. In 2019, SACN agreed to conduct a risk assessment on nutrition and maternal health focusing on maternal outcomes during pregnancy, childbirth and up to 24 months after delivery.

2. SACN agreed that, where appropriate, other expert Committees would be consulted and asked to complete relevant risk assessments e.g. in the area of food safety advice. A provisional list of chemicals was proposed by SACN Members; however, this was subject to change following discussion by COT. A scoping paper was presented to the Committee (TOX/2020/45) to define the scope of the work from the toxicological safety perspective and also requesting their input on the selection of candidate chemicals or chemical classes that could be added or removed.

3. As part of this work, the Committee thought it would be useful to consider the use of dietary supplements during pregnancy. A discussion paper (TOX/2020/51) was presented reviewing the commonly used dietary supplements used during pregnancy. These were supplements that are not officially recommended by relevant authorities, but which are promoted by anecdotal evidence and unofficial sources as having various purported benefits.

4. The review was confined to herbal dietary supplements which would be regulated under food law and which would not be considered to be traditional herbal medicines which are the responsibility of the Medicines and Healthcare Products Regulatory Agency (MHRA). Following this review, the COT suggested ginger required further investigation, noting that both human and animal in vitro and in vivo data were available. Main areas of concern were general toxicity to the mother, effects on the development of the fetus or embryo, and possible interactions with drugs.
Introduction

5. Ginger (*Zingiber officinale*) is a flowering tropical plant originating in Southeast Asia and grown in warm climates including China, India, Africa and the Caribbean. The rhizome (underground stem) of the ginger plant is commonly used as a spice and flavouring in many countries around the world and is increasingly growing in popularity as a natural remedy due to its purported immune system-boosting properties and also for motion sickness and post-operative nausea and vomiting.

6. Ginger supplements are regarded as a “safe” by people looking for a natural alternative for the relief of morning sickness. Some adverse effects have been reported however, few specific safety studies specifically have been carried out in this area. Despite its extensive use among pregnant women, there is limited information on the safety of its use.

7. In the current paper, a literature search was conducted using Google Scholar, PubMed and Science Direct databases to identify studies detailing the use of ginger during pregnancy, using search terms including ‘ginger supplement’, ‘ginger and pregnancy’, and ‘ginger and safety’. The search was centred on papers published between 2010 and 2020. Information was taken from the EMA's review of ginger and recently published reviews of ginger use during pregnancy.

8. Many of the studies found were centred on the efficacy of ginger as a remedy for post-operative, chemotherapy and pregnancy associated nausea and vomiting and few discussed safety aspects of ginger use during pregnancy and pregnancy outcomes.

9. There are currently no health-based guidance values (HBGV) with respect to ginger or its main components. Exposure to ginger was considered based on information found on supplement and tincture composition and background diet, but the variability of available supplements means exposure will also vary.

Uses

10. Ginger is commonly consumed in fresh root form, dried root powder, capsule (encapsulated dried powder) form, liquid extract, preserved in syrup or sugar and as a tea. Ginger is a common traditional treatment for prophylaxis of motion sickness, Digestive disorders, upset stomach and nausea\(^1\). In pregnancy it is most used in the treatment of pregnancy-related nausea (NHS). It has also been used as a dietary supplement and a traditional remedy in many cultures\(^2\). Ginger is included in the official pharmacopoeias of several western countries.

---

\(^1\) Vomiting and morning sickness - NHS (www.nhs.uk)
\(^2\) Ginger: Health Benefits & Side-Effects (webmd.com)
Constituents

11. The ginger rhizome contains two main classes of constituents: the essential oils responsible for the aroma, and the main pungent principles, gingerols and shogaols. Organic acids are also present in smaller amounts. Depending on area of cultivation, gingerols make up 4-7.5% of the pungent principles, the main one being 6-gingerol. Gingerols of other chain lengths are also present in smaller amounts.

12. Over 100 compounds have been identified, most of them being terpenoids mainly sesquiterpenoids (α-zingiberene, β-sesquiphellandrene, β-bisabolene, α-farnesene, ar-curcumene (zingiberol) and smaller amounts of monoterpenoids (camphene, β-phellandrene, cineole, geraniol, curcumene, citral, terpineol, borneol) (EMA, 2012). Relative amounts of the main principles and relative concentrations of gingerol to shogaol differ according to preparation and processing.

6, 8 and 10-Gingerol

6-Shogaol

Essential oils

13. The major components of essential oils found in ginger include camphene, sabinene, α-curcumene, zingiberene, α-farnesene, β-sesquiphellandrene and geranial. The principle organic acids found in ginger include included citric, malic, oxalic, succinic, and tartaric acids. Animal models suggest one of the major components of ginger – 6-gingerol – is eliminated partially in the liver (Naora et al., 1992).

Toxicity

14. Ginger is classified as ‘Generally Recognised as Safe’ (GRAS) by the FDA however few specific studies have been carried out to evaluate the safety of ginger use during pregnancy and lactation. Recently, the Finnish Food Authority has issued a recommendation against the use of products containing ginger concentrate or
extract, ginger tea and food supplements containing ginger by pregnant and breastfeeding women, infants and toddlers, schoolchildren, elderly and individuals with weakened immunity. It was noted that the concentrates contained harmful substances and safe consumption levels were unknown. In 2008, the Danish company Ferrosan A/S withdrew their product GraviFrisk – a product containing 6 g of dried ground ginger - from market, due to concerns surrounding the lack of safety data with respect to the use of supplements containing highly concentrated ginger extracts by pregnant women (Dietz et al., 2016).

15. Ginger has been reported to cause heartburn (Vutyavanich et al., 2001, Chittumma et al., 2007 abstract only), exacerbate lower gastrointestinal tract conditions such as irritable bowel syndrome and duodenal ulcer, hypotension and there is a theoretical possibility of cardiac arrhythmias associated with ginger use (Tiran 2012). Very large doses of 6 g are reported to possibly lead to gastric irritation and loss of protective gastric mucosa (Supu et al., 2018).

Health based guidance values

16. There are currently no health-based guidance values (HBGV) with respect to ginger use during pregnancy and no consensus on the safe dosage of ginger. The UK Teratology Information Service (UKTIS) have concluded that while exposure to ginger would not usually be regarded as grounds for termination or additional monitoring during pregnancy, other factors could affect the overall risk outcome, and this is something that would take place on an individual basis.

Toxicity studies

Cytotoxicity

17. The cytotoxicity of ginger has been investigated with varied results. Plengsuriyakarn et al. examined cytotoxicity in Cholangiocarcinoma (CCA) cell line 6 (CL-6), hepatocarcinoma (HepG2) and normal human renal epithelium (HRE) models using calcein-AM release and Hoechst 33342 assays. Median inhibitory concentration, (IC50) and value for cytotoxicity of the crude ethanolic extract of ginger were 10.95 and 53.15, µg/ml respectively.

18. Zaeoung et al. (2005) reported that the IC50 of ginger was higher than 39.2 µg/ml against breast (MCF7) and colon (LS174T) cell lines. Abudayyak et al. found the aqueous and methanol extracts of ginger exhibited no cytotoxic activity when

3 GENERAL INSTRUCTIONS ON SAFE USE OF FOODSTUFFS (ruokavirasto.fi)

4 USE OF GINGER IN PREGNANCY (medicinesinpregnancy.org)
assessed using an MTT test in rat kidney, NRK-52E cell line. The chloroform extract resulted in a IC$_{50}$ value of 9.08 mg/mL (2015).

Mutagenicity

19. Nakamura & Yamamoto (1982) found that the juice of ginger rhizome possessed both mutagenic and anti-mutagenic properties, and that 6-gingerol in particular was a powerful mutagen. The group also demonstrated that 6-shogaol was much less mutagenic (strain Hs30 of Escherichia coli) than 6-gingerol (Nakamura & Yamamoto 1983). In a *Salmonella typhimurium* reverse mutation (Ames) assay, the urine of rats fed diets containing 0.5, 1 and 5% powdered ginger for 1 month and exposed to benzo(a)pyrene was found to display a significant reduction in the mutagenicity as indicated by a reduced number of TA98 and TA100 revertants at all ginger concentrations (Nirmala *et al.* 2007) when tested in an Ames assay.

20. In another Ames assay, an ethanol extract of ginger (*Soudamini et al.* 1995) and an essential oil from ginger (*Sivaswami et al.* 1991) demonstrated mutagenic activity in *S. typhimurium* strains TA 100 and TA 1535 at concentrations of 25-50 mg/plate and 5-10 mg/plate, respectively. Similarly, an ethanolic ginger extract at concentrations between 10 and 200 μg/plate, and gingerol and shogaol were mutagenic in strains TA 100 and TA 1838 with metabolic activation by rat liver S9 fraction, while zingerone did not display mutagenic effects (Nagabhushan *et al.* 1987).

21. Abudayyak *et al.* found the aqueous ginger extract exhibited mutagenic activity when assessed using the Ames assay on *S. typhimurium* TA98 (-S9) strains. no activity was observed in the chloroform and methanol extracts (2015).

Animal studies

Acute toxicity

22. An acute toxicity study carried out by Malik and Sharma on male Wistar rats showed no signs of toxicity or mortality (2011). The animals were administered doses of 250, 500 and 1000 mg/kg by gastric gavage. The authors stated that the three dose levels used in the study corresponded to 5, 10 and 20% of the NOAEL of the lyophilised ginger powder (5000 mg/kg).

23. Plengsuriyakarn *et al.* also examined acute and subacute toxicity in hamsters. Sixty hamsters (nine groups of 5 male and 5 female) were fed either 1000, 3000 or 5000 mg/kg bw ethanolic ginger extract, resuspended in a distilled water-Tween-80, mixture 4:1, v:v, by oral gavage and observed for 14 days (acute toxicity) or 30 days (subacute toxicity). The group concluded an absence of any toxicity at maximum dose of 5 g/kg bw during the investigation period.
Short term repeat dose studies

24. Rong et al. (2009) evaluated the safety of powdered Japanese ginger (mainly containing 6-gingerol galanolactone and 6-shogaol) by conducting a 35-day toxicity study in rats. Both male and female rats were treated with 500, 1000 and 2000 mg/kg bw/day by gavage. The results demonstrated that oral administration of up to 2000 mg/kg to male and female rats did not result in any increase in mortality, or changes to behaviour, growth, the general condition of the animals (including: changes in skin, fur, eyes, and mucous membranes, occurrence of secretions, excretions and autonomic activity), food and water consumption. It was only at the highest dose tested (2000 mg/kg), that ginger led to slightly reduced absolute and relative weights of testes (by 14.4% and 11.5%, respectively). No effects were apparent in the females.

25. The effect of oral and intraperitoneal administration of aqueous extracts of ginger root over 28 days in female rats at two dose levels (50 mg/kg and 500 mg/kg) was examined for haematological, serum and systemic toxicity (Alnaqeeb et al. 2003). Neither oral nor intraperitoneal administration resulted in mortality. Orally administered aqueous ginger extract resulted in increased levels of serum aspartate aminotransferase (AST) and decreased levels of alanine aminotransferase (ALT).

26. Jeena et al., conducted a sub chronic toxicity study of the essential oil of ginger in Wistar rats following oral administration at concentrations of 100, 250, and 500 mg/kg per day once daily for 13 consecutive weeks to assess the oral safety of ginger oil (2011). No mortality was observed. No unusual changes in behaviour or locomotor activity were observed during the period of the study, nor were any abnormal changes observed in the relative organ weights of liver, kidney, spleen, lungs, brain, and stomach with respect to body weight in ginger oil-treated animals when compared to vehicle control animals.

27. An increase in serum sodium levels was observed in male rats treated with 500 mg/kg per day but in the absence of changes in sodium levels in females, this change was not considered significant. A slight increase in total bilirubin was observed in female rats treated with ginger oil along with a decrease in AST and ALT levels however, there was no significant changes in hepatic function parameters such as alkaline phosphatase, total protein, albumin, and globulin content.

Reproductive and developmental toxicity

28. Reproductive and developmental toxicity has also been investigated in rat studies. In a study by Wilkinson (2000), three groups of pregnant Sprague-Dawley rats were administered either a control (unspecified), or 20 g/L or 50 g/L ginger tea -
prepared by the infusion of grated ginger in water via their drinking water - during days 6 to 15. No further details were provided regarding specific compounds of interest. While no maternal toxicity was observed, embryonic loss in the treated groups was found to be double that of the controls. Exposed foetuses were found to be significantly heavier than controls and showed no gross structural malformations. The results of this study suggest that in utero exposure to ginger tea results in early embryonic loss and increased growth in surviving foetuses.

29. Hosseini et al. investigated the effect of ethanolic ginger extract on serum testosterone, LH and FSH as well as effect on spermatogenic cell lines in male mature offspring rats (2015, abstract only). In this study, 72 female rats, sorted into 9 groups were orally administered of alcoholic extract of ginger at doses of 50, 100 and 200 mg/kg bw, during their neonatal and perinatal periods versus saline as a control. Following puberty, LH, FSH, cell numbers of Sertoli, spermatogonia, spermatocyte and spermatids were counted in 8 male rat offspring from each group. Ginger was found to significantly increase testosterone levels and the number of spermatogenic cells and at doses of 100 and 200 mg/kg bw, alcoholic extract of Ginger significantly reduced the FSH and LH compared to control groups. The authors concluded that "the oral consumption of Ginger during pregnancy and lactation dose-dependently increase the level of testosterone and the number of spermatogenic cells."

30. The teratogenicity of EV.EXT 33, a patented Zingiber officinale extract (comprising 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, and 8-shogaol, which made up 1.9 w/w of the extract) was investigated in Wistar rats, (Weidner & Sigwart, 2001). The extracts were administered orally by gastric intubation at concentrations of 100, 333 and 1000 mg/kg, to three groups of pregnant rats from days 6 to 15 of gestation. Their bodyweight, food and water monitored during the treatment period. The study concluded that treatment with EV.EXT 33 during the period of organogenesis resulted in neither maternal nor developmental toxicity at daily doses of up to 1000 mg/kg bw.

31. Dissabandara & Chandrasekara (2007) also examined the effect of powdered ginger extract administered prenatally on the postnatal development of rats. A period of administration of the dry powdered extract orally at doses of 500 mg/kg/day or 1000 mg/kg/day (control not specified) during days 5 to 15 of gestation resulted in a lower intake of food and water and lower weight gain in the ginger treated group, suggesting that maternal administration of ginger during mid pregnancy resulted in reduced maternal weight gain and increased embryonic loss without affecting the postnatal growth and physical maturation of the surviving offspring.

32. ElMazoudy and Attia (2018) investigated the effect of powdered dried ginger root on the oestrus cycle and implantation in female mice. ICR mice, orally dosed at 250, 500, 1000, or 2000 mg/kg bw/d aqueous ginger extract. These were investigated in four different experiments: the main study of outcomes (treatment for
90 days and throughout mating and gestation), a 35-day treatment study evaluating effects on the oestrous cycle. The third and fourth intended antifertility and abortifacient loss (20 days treatment). In the main study, the dams were sacrificed on gestation day 20. One mortality was recorded in the 100mg/kg bw/d group on gestation day 18 and two mortalities in the 2000 mg/kg bw/d group at day 16. There was also a significant reduction in body weight change in these two dose groups compared to the control group; however, food consumption was comparable.

33. In the study investigating the oestrus cycle, a significant reduction in the numbers of oestrus cycles was observed at the highest dose group, with the length of the oestrus cycle in this group being significantly prolonged (10.05 ±0.8) days compared with (4.99 ± 0.5) days recurrent and successive oestrous cycles in control mice. At the highest dose level, the length oestrous cycle was prolonged with a significant decrease in the duration of diestrous-metestrus (luteal) phase and prolonged proestrus-estrus (ovulatory) phase. In the study investigating pre-implantation loss, a significant decrease in the number of corpora lutea was observed at the highest dose group. Implantation failure was also increased by 36% compared to the control group and pre-implantation loss at this dose group was also 16.59% higher than the control group. The authors considered that this may reflect a dose-depend antifertility (anti-implantation) effect.

34. Regarding fertility and developmental outcomes, the female copulation index was significantly reduced at 2000 and 1000 mg/kg bw/d groups, whereas the female pregnancy index was significantly decreased only at the highest dose. The number of implantation sites and live fetuses in the 2000 mg/kg bw/d group were lower than the other treated and control groups. An increase in fetal resorption and post implantation loss was also seen at the highest dose group. There was no evidence of fetal malformations however growth retardation, reduced pup weight and delay in the crown-rump length was observed at this dose group as well. Finally, changes in ovarian histopathology were observed at 2000 mg/kg bw/d, following 90 days of treatment. Ovarian follicle atresia was observed. The atretic follicles contained cell debris and there was haemorrhage in the antral cavity.

35. Additionally, degenerated primordial follicles with pyknotic nuclei forming polycystic ovaries were noted. Deteriorated follicles were observed as a detaching of layers of granulosa cells from the basal membrane by dilation of zona pellucida and with evidence of apoptosis in damaged ova follicular nuclei were non-visible. The authors considered the above observations as evidence that ginger possesses anti-ovulation properties. Overall, the authors concluded that ginger impairs the normal growth of corpus luteum because of progesterone insufficiency during early pregnancy and that the results suggested that ginger can disrupt the oestrous cycle and blastocyst implantation without teratogenesis. They considered the highest NOAEL to be 500 mg/kg bw.
Human studies - exposures in pregnancy

36. In their 2003 review of interventions for nausea and vomiting in early pregnancy, Jewell and Young concluded that ginger shows no evidence of teratogenicity in infants (Jewell and Young, 2003). More recently, Stanisiere et al. (2018) conducted a review of the safety and efficacy of ginger rhizome for decreasing nausea and vomiting in women during early pregnancy. This review was based on systematic literature searches until the end of December 2017. Most of the studies included in this review have already been included in the current paper. Some recent studies have been conducted evaluating the effectiveness and safety of ginger in pregnancy, and these will be discussed in detail. Overall, most studies reported gastrointestinal effects such as abdominal discomfort, vomiting and diarrhoea. Other effects included dizziness, headaches and drowsiness with some more serious effects such as spontaneous abortion also being reported in 5 out of the 14 randomized clinical studies. The review focuses on the reported effects rather than statistical significance, therefore more details on studies reporting more serious effects are given below.

37. In a double-blind randomised crossover trial, 27 women were administered capsules containing either 250 mg ginger in powdered root form or 250 mg lactose as a placebo, four times per day, for four days followed by a wash out period of 2 days prior to a further 4 days administration of ginger or placebo (Fischer-Rasmussen et al., 1990). Two subjects did not carry to term: One subject from the ginger group had a spontaneous abortion, one elected. Of the remaining 25 subjects, no adverse effects were observed.

38. Of the available human studies, few explicitly addressed the safety of ginger consumption during pregnancy, most being incidental to other studies. In a double-blind study by Vutyavanich et al. (2001), 32 women were given 1 g of dried ginger in capsule form for 4 days. Of those in the ginger group, one spontaneous abortion was reported compared to 3 in the placebo group. Equally, for delivery by caesarean section, there was no difference between both groups. No congenital abnormalities were observed in all babies carried to term. The group concluded that there were no significant adverse effects of ginger on pregnancy outcome.

39. An observational study in humans examined pregnant women who took ginger in their first trimester and compared them to women exposed to nonteratogenic drugs that were not antiemetic drugs. The results suggested that the ginger group did not have an increased rate of major malformations above the baseline rate of 1%–3% (Portnoi et al., 2003). Three major malformations were reported in the ginger group, ventricular septal defect (VSD), right lung abnormality, and kidney abnormality (pelviectasis) and one child was diagnosed with idiopathic central precocious puberty at age 2 years. The mother was reported to have taken 250 mg of ginger in capsules four times a day from 11 to 20 weeks of gestation in addition to dimenhydrinate and doxylamine/vitamin B6 (Diclectin) during the first
trimester of pregnancy. No significant difference between the two groups in terms of live births, spontaneous abortions, stillbirths, therapeutic abortions, birth weight, or gestational age were reported, however the comparison group had more infants weighing less than 2500 g and the ginger group had 8 sets of twins.

40. Willetts et al. examined the effect of ginger on pregnancy induced nausea (2003). 120 women less than 20 weeks pregnant, were given 125 mg ginger extract (EV.EXT35; equivalent to 1.5 g of dried ginger) or a placebo four times per day for 4 days. Three spontaneous abortions were observed in the group receiving ginger compared to those in the placebo group. Whilst also examining the use of ginger in the treatment of nausea and vomiting in pregnancy, Smith et al. noted 3 spontaneous abortions in the group taking 1.05 g ginger compared to 9 abortions in the group taking 75 mg B6 daily for 3 weeks (2004).

41. Ensiyeh et al., investigated the effectiveness of ginger versus B6 for treatment of NVP (2009) in women before 17 weeks’ gestation. 70 women were randomised to receive either ginger at a dose of 1 g per day or B6 and 40 mg per day for 4 days. The ginger group reported 2 spontaneous abortions, compared to one in the B6 group. Of the babies brought to term, no congenital anomalies were observed, and all babies were discharged in good condition.

Lactation

42. With respect to lactation, the focus of available studies has been on the effect of ginger on milk production and volume rather than safety and therefore, the effect of exposure during lactation has not been fully investigated. Ginger has reportedly been used as a galactagogue in Turkey and parts of Asia (Lamxay et al., 2011, Kaygusuz et al., 2021), and has been demonstrated to possibly enhance milk production in women who had vaginal births (Dilokthornsakul et al., 2021), though the mechanism for this effect is unclear. Overall, ginger has not previously been considered a galactagogue for pregnant women.

Effect on Cytochrome P450 Enzymes and Herb-Drug Interactions

43. Qiu et al. (2015) investigated the molecular interactions between 12 main active components (6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, 8-shogaol, 10-shogaol, ar-curcumene, β-bisabolene, β-sesquiphelandrene, 6-gingerdione, (-)-zingiberene, and methyl-6-isogingerol) and human cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4 and attempted to predict the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the 12 ginger components using computational methods and literature searches. This study suggests that ginger components may regulate the activity and expression of various human CYPs, resulting in alterations in drug clearance and response.
44. These results could potentially be significant in pregnant women on medication, who are using ginger as a remedy for nausea in the early stages of pregnancy.

In vitro studies

45. Ginger extracts and the major components thereof - 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) and 6-shogaol (6S) - were investigated and shown to have an inhibitory effect on CYP isoenzymes in \textit{in vitro} models by various groups (Kimura et al., 2010; Kim et al., 2012; Mukkavill et al., 2014).

Animal studies

46. A study into the effect of ginger on the pharmacokinetics of metronidazole was studied by Okonta et al., using rabbits (2008). In a two-phase study, five healthy local strain rabbits (3 females, two males) were each given 3 mg/kg oral metronidazole. Following a 2-week washout period, the rabbits were given 1 ml/kg of ginger extract orally daily for 3 days and immediately given 3 mg/kg metronidazole per oral on the third day. Ginger significantly increased the absorption and plasma half-life, and significantly decreased the elimination rate constant and clearance of metronidazole.

47. Egashira et al., reported the interaction between ginger juice and tacrolimus in rats (2012). Tacrolimus (0.6 mg/kg) was administered intraduodenally in male Sprague-Dawley rats 1 hr following oral administration of 10 mL/kg 50% ginger juice or water. Pre-treatment with ginger juice was found to significantly increase tacrolimus blood concentrations compared to those pre-treated with water or orange juice.

48. The possible herb-drug interaction of ginger crude extract on glibenclamide and insulin was investigated by Al Omari et al., along with its hypoglycaemic and antihyperglycemic effects in normoglycemic- and streptozotocin-induced (STZ) diabetic rats (2012). Ginger crude extract was administered to normoglycemic male rats as a single dose (1 day) and as a daily dose for 1 week. STZ diabetic rats were treated with the same GCE concentrations (25, 50 and 100 mg/kg bw) together with glibenclamide (5 mg/kg bw) or insulin (1.2 IU/kg bw).

49. Single administration of ginger crude extract showed a significant decrease in blood glucose level (BGL) in normoglycemic rats after 1 and 2 hours (50 mg/kg bw). In STZ- diabetic rats ginger crude extract (25 and 50 mg/kg bw) decreased non-fasting BGL (N-FBGL) significantly at 1.5, 2.5, 3.5 and 4.5 hours. Glibenclamide (5 mg/kg bw) in combination with ginger crude extract at doses 25 or 50 mg/kg bw exhibited a significantly reduction in the N-FBGL 26.3% and 25.1% respectively after 4.5 hours, compared to glibenclamide alone which exhibited a 7.9% reduction.
50. Ginger was found to have a significant inhibitory effect on CYP3A4, CYP2C9, and P-glycoprotein activities in vitro (Kimura et al., 2010; Zhang and Lim, 2008). It was this effect that was thought to be responsible for reported hepatic cytolysis in a 48-year-old woman being treated with crizotinib. The patient, who was being treated with 250 mg crizotinib twice a day, had been taking ginger as a tea (amounts unknown) concomitantly during treatment. A subsequent diagnostic evaluation showed an increased crizotinib concentration, 1.8-fold higher than that measured two months prior.

Anti-platelet aggregation activity

51. Several reports have been published on the pharmacological properties of ginger, with varying results. The potential effect of ginger extract and components thereof on the reduction of platelet aggregation and their potential antithrombotic activity has been noted as a concern in both literature and by health professionals.

52. With regards to the relevance of such effects in pregnancy, literature reports that pregnancy is associated with an increased incidence of thrombotic events; mainly related to a pro-thrombotic state, physiologically useful to reduce bleeding at delivery. These changes are more pronounced in the third trimester (Patti et al., 2014). It has also been hypothesised that antiplatelet agents might prevent or delay the development of pre-eclampsia (Duley et al., 2019).

53. The implications and clinical significance of the anti-platelet activity of ginger exposure during different stages of pregnancy remain undetermined.

In vitro studies

54. Srivastava reported an effect of ginger extracts on in vitro platelet aggregation (1986). Ginger extracts in water, n-hexane, chloroform, and ethyl acetate were shown to inhibit platelet aggregation using arachidonic acid (AA), epinephrine, adenosine diphosphate (ADP), and collagen as agonists.

55. The effect of an aqueous ginger extract on platelet thromboxane-B2 (TBX₂) and prostaglandin-E₂ (PGE₂) production was studied by Thomson et al. (2002). Adult female Sprague-Dawley rats were administered an aqueous extract of raw ginger at either 50 mg/kg or 500 mg/kg daily, by either oral gavage or intraperitoneally (IP) for a period of 4 weeks. A dose of 50 mg/kg ginger administered orally, or IP did not result in any significant reduction in serum thromboxane-B₂ levels when compared to saline-treated control groups but doses at 500 mg/kg significantly reduced TBX₂ levels in serum.

56. A non-significant reduction in the level of TXB₂ was observed when ginger was injected IP. However, levels were not significantly different from the TXB₂ levels in control rats that had received saline. 50 mg/kg of ginger administered orally resulted in serum PGE₂ levels being significantly reduced however, 500 mg/kg was found to be more effective in reducing PGE₂ synthesis. PGE₂ levels were reported to
be significantly lower than the saline control in rats given 500 mg/kg ginger extract both orally and IP.

Human studies

57. Srivastava (1989) investigated the effect of fresh ginger on blood platelet thromboxane synthesis in humans. In a study on 7 women aged between 25-65 years, where volunteers consumed ~5g of fresh ginger for 7 days. Ginger was found to inhibit eicosanoid biosynthesis in vivo.

58. Krüth et al. reported the possible over-anticoagulation resulting from a possible ginger-phenprocoumoun interaction (2003). A 76-year-old woman on long-term phenprocoumoun therapy presented with epistaxis and an international normalized ratio (INR) of >10. Partial thromboplastin time (PTT) was also found to be prolonged (84.4 seconds; normal <35). For several weeks prior to the event, the woman had a regular ginger intake of dried ginger prices and tea from ginger powder. Following treatment with vitamin K, the patient’s INR and PTT returned to within therapeutic range.

59. Young et al. investigated the synergistic effect of ginger and nifedipine on anti-platelet aggregation in healthy volunteers aged 25-60 years old and hypertensive individuals aged 35-60 years old (2006). In a five-part study, the two groups comprising of 10 males and 10 females were administered 75 mg of acetylsalicylic acid (ASA), 1 g of ginger, 10 mg nifedipine, 1 g ginger and 10 mg nifedipine in combination and 1 g ginger and 75 mg ASA in combination daily for one week each following a washout period (7 days following ASA administration, 10 days thereafter).

60. Platelet aggregation in the presence of collagen ADP and epinephrine was 44.1%, 44.5% and 42.1% in normal subjects and 64.2%, 67.7% and 62.9% in hypertensive patients, respectively. Platelet aggregation induced by collagen, ADP or epinephrine was found to be higher in hypertensive patients than normal patients. Following administration of ginger alone, platelet aggregation was measured as 35.2%, 37.8%, 35.9% with collagen, ADP and epinephrine respectively. When administered ginger and nifedipine in combination, the percentage inhibition of platelet aggregation induced by collagen, ADP and epinephrine were 79.8%, 75.2%, 69.3% respectively.

61. Rubin et al. (2019) reported the possible effect of ginger supplementation on the (INR) in a woman taking warfarin. The 70-year-old female, who had been taking clonazepam 1 mg, metoprolol succinate 25 mg, paroxetine 10 mg, phenytoin 30 mg, rosvastatin 20 mg, warfarin 7.5 mg daily, and warfarin 10 mg once day per week, presented with an INR of 8, an increase from 2.7 one month prior after taking a 48 mg ginger supplement daily. A week following cessation of the ginger supplement, the INR declined to 2.6.
62. Al Askar et al. (2020) investigated the effect of ginger on platelet aggregation using agonists adenosine diphosphonate, arachidonic acid, collagen, ristocetin and epinephrine. Forty healthy male and female participants were randomized (1:1) to consume ginger tea at an amount of 4 g in 150 ml of boiling water once daily vs. 4 g twice daily for five consecutive days. 4 g of ginger powder administered daily resulted in reduced platelet aggregation in subjects using epinephrine only. Platelet aggregation inhibition was also found to be higher in women using arachidonic acid.

Effects on blood pressure

63. Ghayur and Gilani (2005) reported that a crude extract of ginger induced a dose-dependent (0.3–3 mg/kg) fall in arterial blood pressure of anesthetized Sprague-Dawley rats (2005). In Guinea pig paired atria, the crude extract exhibited cardio-depressant activity on the rate and force of spontaneous contractions. In rabbit thoracic aorta preparation, the crude extract relaxed the phenylephrine induced vascular contraction at a dose 10 times higher than that required against K+-induced contraction (80 mM).

64. Ca²⁺ channel-blocking (CCB) activity was confirmed when the crude extract shifted the Ca²⁺ dose–response curves to the right similar to the effect of verapamil. It also inhibited the phenylephrine (1 mM) control peaks in normal-Ca²⁺ and Ca²⁺-free solution, indicating that it acts at both the membrane-bound and the intracellular Ca²⁺ channels. When tested in endothelium-intact rat aorta, it again relaxed the K+-induced contraction at a dose 14 times less than that required for relaxing the PE-induced contraction. The vasodilator effect of the crude extract was endothelium-independent because it was not blocked by Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) (0.1 mM) or atropine (1 mM) and also was reproduced in the endothelium-denuded preparations at the same dose range. These data indicate that the blood pressure-lowering effect of ginger is mediated through blockade of voltage-dependent calcium channels.

Exposure

65. The relative proportions of the active components of ginger – gingerols, shogaols and curcumin occur in varying proportions, depending on the variety of rhizome and the area of cultivation.

66. Many ginger supplements are recommended to support digestive and joint health, alleviate nausea, upset stomach, and travel sickness. Currently, two commercially available pregnancy supplements – ‘Seven Seas Pregnancy’ and ‘Seven Seas Pregnancy Plus Follow On’ – contain 10 mg ginger extract (Table 1).
Table 1. Sample of ginger supplements in capsule and tablet form commercially available

<table>
<thead>
<tr>
<th>Commercial Product Name</th>
<th>Form</th>
<th>Composition</th>
<th>Daily dose recommended by vendor or website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seven Seas Pregnancy</td>
<td>Tablet</td>
<td>Ginger extract 10mg</td>
<td>1 tablet a day.</td>
</tr>
<tr>
<td>Seven Seas Pregnancy</td>
<td>Tablet, capsule</td>
<td>Ginger extract 10mg</td>
<td>One tablet and one capsule/day</td>
</tr>
<tr>
<td>Plus Follow-On</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supplemented</td>
<td>Tablet</td>
<td>Ginger Extract 3,000 mg (20:1)</td>
<td>1-2 tablets daily</td>
</tr>
<tr>
<td>Good n Natural</td>
<td>Capsule</td>
<td>Powdered root 550 mg</td>
<td>2 capsules daily</td>
</tr>
<tr>
<td>Woods Supplements</td>
<td>Tablet</td>
<td>Ginger extract 500 mg</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Solgar</td>
<td>Capsules</td>
<td>Ginger (Zingiber officinale) Root Powder 150mg, Standardised</td>
<td>1-2 capsules daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ginger (Zingiber officinale) Root Powdered Extract (5% ginger gengerols) 300mg</td>
<td></td>
</tr>
<tr>
<td>Solgar</td>
<td>Capsules</td>
<td>Ginger (Zingiber officinale) Root Powder 500mg. Ginger (Zingiber officinale) Root Powdered Extract (4:1) 5mg.</td>
<td>1-3 capsules daily</td>
</tr>
<tr>
<td>Swanson</td>
<td>Capsules</td>
<td>Ginger Root 540 mg</td>
<td>2 capsules daily</td>
</tr>
<tr>
<td>Bio Health</td>
<td>Capsules</td>
<td>Ginger Root 500mg</td>
<td></td>
</tr>
<tr>
<td>Biovea</td>
<td>Capsules</td>
<td>Ginger (root) (std. to 5% gingerols, 12.5 mg) 250 mg</td>
<td>1-3 daily</td>
</tr>
<tr>
<td>Jarrow Formulas</td>
<td>Capsules</td>
<td>Ginger root (concentrate) (Zingiber officinale) 500 mg</td>
<td>1 daily</td>
</tr>
<tr>
<td>Nature’s Best</td>
<td>Capsule</td>
<td>Ginger Root 14,400mg (provided by 120mg of a 120:1 extract) providing 24mg gingerols</td>
<td>1 daily</td>
</tr>
<tr>
<td>NeuLife</td>
<td>Tablets</td>
<td>Ginger Extract 12000 mg</td>
<td>1-2 tablets daily</td>
</tr>
<tr>
<td>Lifeplan</td>
<td>Capsule</td>
<td>Ginger 12:1 Extract</td>
<td>1-2 tablets daily</td>
</tr>
<tr>
<td>ALPHA01</td>
<td>Capsules</td>
<td>Ginger root powder 1100 mg</td>
<td>2 capsules daily</td>
</tr>
<tr>
<td></td>
<td>Tablet</td>
<td>Ginger Extract 12,000mg (20:1) standardised to 600mg 12,000mg</td>
<td>1-2 tablets daily</td>
</tr>
<tr>
<td>Now Foods</td>
<td>Capsules</td>
<td>Ginger Extract (Zingiber officinale) (Root) (Standardized to min. 5% Gingerols) 250 mg: Ginger Powder (Zingiber officinale) (Root) 225 mg</td>
<td>1-3 capsules daily</td>
</tr>
<tr>
<td>Superfood World</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viridian Ginger</td>
<td>Capsules</td>
<td>One vegetarian capsule provides: Certified organic Ginger root 400mg</td>
<td>1-3 capsules daily</td>
</tr>
</tbody>
</table>
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

Table 2: Sample of ginger supplements in liquid and powder forms commercially available

<table>
<thead>
<tr>
<th>Commercial Product Name</th>
<th>Form</th>
<th>Composition</th>
<th>Daily dose recommended by vendor or website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indigo Herbs</td>
<td>Tincture</td>
<td>Zingiber officinale, Alcohol, Water. Extraction Ratio: 1:3, Alcohol Volume: 25%</td>
<td>1-2 ml, 2-3 times daily 20 drops from the glass dropper equals ~ 1 ml</td>
</tr>
<tr>
<td>Nature's Answer</td>
<td>Tincture</td>
<td>Ginger (Zingiber officinale) root extract: 145 mg</td>
<td>1 ml (28 drops) three times per day</td>
</tr>
<tr>
<td>Herb Pharm</td>
<td>Tincture</td>
<td>Ginger rhizome (Zingiber officinale) extract 598 mg (Extraction rate 140 mg herb per 0.7 ml)</td>
<td>“1 full squeeze of the dropper bulb to 2 oz. of water or juice, 2 - 5 times per day.</td>
</tr>
<tr>
<td>Indigo Herbs</td>
<td>Powder</td>
<td>100% Pure Zingiber officinale Powder</td>
<td>1/3 teaspoon powder in water 3 times a day. (1 tsp = 3g)</td>
</tr>
<tr>
<td>Organic Herbal Remedies</td>
<td>Tincture</td>
<td>Herb to pure grain alcohol of 1:3. 1ml is the equivalent of 333mg of dried ginger root. W</td>
<td>0.2ml to 0.4ml three times a day in a little water. Children 6-12 years old 0.1ml to 0.2ml three times a day</td>
</tr>
<tr>
<td>Biovea</td>
<td>Tincture</td>
<td>Fresh Organic Ginger (root) (667 mg per 1 ml serving)</td>
<td>30 drops (~ 1 ml), 1-3 times daily or as needed</td>
</tr>
<tr>
<td>Epigenar</td>
<td>Tincture</td>
<td>Purified water, organic alcohol, organic ginger (Zingiber officinale) (amounts not specified)</td>
<td>15 drops, 3 times daily Max 60 drops per day unless otherwise advised. Children aged 4-15 years, 3 times daily, one drop per number of years of age.</td>
</tr>
</tbody>
</table>

Consideration of ginger from other sources

67. In addition to supplements, pregnant women may also consume ginger as part of their general diet to various degrees. There are anecdotal reports of women using ginger products such as ginger biscuits and ginger ale, to alleviate morning sickness and nausea. Some may use these in combination with juice shots or tinctures.
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

**Table 3:** Sample of ginger-containing foods commercially available

<table>
<thead>
<tr>
<th>Commercial product name</th>
<th>Form</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Border Biscuits Dark Chocolate &amp; Ginger</td>
<td>Ground ginger</td>
<td>Ground ginger 1.5 %</td>
</tr>
<tr>
<td>Sainsbury’s Stem Ginger Cookies, Taste the Difference</td>
<td>Stem ginger</td>
<td>Candied Stem Ginger (17%) (Australian Stem Ginger, Sugar); ginger powder</td>
</tr>
<tr>
<td>Sainsbury’s Dark Chocolate &amp; Ginger Cookies, Taste the Difference</td>
<td>Stem ginger</td>
<td>Candied Stem Ginger (13%) (Australian Stem Ginger, Sugar); ginger powder</td>
</tr>
<tr>
<td>Nairn’s Wheat Free, Ginger Biscuits</td>
<td>Stem ginger</td>
<td>Stem Ginger (6.4%) (Stem Ginger, Sugar); Ground Ginger</td>
</tr>
<tr>
<td>Sainsbury’s Ginger Nut Biscuits, SO Organic</td>
<td>Powdered ginger</td>
<td>Ginger Powder (0.6%)</td>
</tr>
<tr>
<td>Nooro Lemon + Ginger CBD Bar</td>
<td>-</td>
<td>Organic gluten free oat flour (33%), organic coconut oil (24%), organic coconut flower sugar, organic almonds, organic chia seeds (5%), organic lemon zest (1.3%), organic lemon oil, organic ginger powder (0.4%),</td>
</tr>
<tr>
<td>Rhythm 108 Lemon, Ginger &amp; Chia Biscuit Share Bag</td>
<td>Dried ginger powder</td>
<td>-</td>
</tr>
</tbody>
</table>

**Table 4:** Ginger containing teas, juices and drinks commercially available

<table>
<thead>
<tr>
<th>Commercial Product Name</th>
<th>Form</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gimber</td>
<td>liquid</td>
<td>38% organic and high-quality ginger, organic lemons, herbs and spices</td>
</tr>
<tr>
<td>Moju</td>
<td>liquid</td>
<td>Apple, Ginger Root (25%), Lemon, Antioxidant: Ascorbic Acid</td>
</tr>
<tr>
<td>James White Drinks Organic Ginger Zinger Shot 70ml</td>
<td>liquid</td>
<td>Organic Apple Juice (73%), Organic Ginger Juice (27%), Water, Antioxidant: Ascorbic Acid</td>
</tr>
<tr>
<td>James White Drinks Organic Xtra Ginger Zinger Shot 70ml</td>
<td>liquid</td>
<td>Organic Apple Juice (59.5%), Organic Ginger Juice (40%), Organic Chilli Flavouring (0.5%), Antioxidant: Ascorbic Acid</td>
</tr>
<tr>
<td>Twinings Lemon &amp; Ginger Tea</td>
<td>Tea</td>
<td>Ginger Root* (37%), Natural Lemon Flavouring with Other Natural Flavourings (25%), Lemongrass*, Blackberry leaves*, Lemon Peel, Sweet Fennel*, Natural Ginger Flavouring with Other Natural Flavourings (3.5%),</td>
</tr>
<tr>
<td>Pukka Organic Ginger, Galangal &amp; Golden Turmeric Tea</td>
<td>Tea</td>
<td>Ginger Root (52%)</td>
</tr>
<tr>
<td>Belvoir Ginger Cordial</td>
<td>Drink</td>
<td>Pressed Ginger Juice 2%, Ginger Extracts,</td>
</tr>
<tr>
<td>Old Jamaica Ginger Beer Light</td>
<td>Drink</td>
<td>Ginger root extract</td>
</tr>
<tr>
<td>Fever Tree Ginger Beer Light</td>
<td>Drink</td>
<td>Ginger Root, Natural Ginger Flavouring with other Natural Flavourings</td>
</tr>
</tbody>
</table>
### Background Exposure from the diet

#### Consumption estimates based on the NDNS

68. Table 5 provides consumption estimates for women of childbearing age - (16 - 49 years) 1 from years 1 – 8 of the NDNS survey (Bates et al., 2014; 2016; Roberts et al., 2018). The NDNS (Bates et al., 2014; 2016; Roberts et al., 2018) does not provide data for pregnant or lactating women so while data is based on women of childbearing age, this data may not necessarily be representative of the maternal diet. The food group used for the consumption assessment consisted of all foods within the NDNS database which contained ginger (raw, powdered etc) except for alcoholic beverages. Mean chronic ginger consumption from the diet of women aged 16-49 years old was 0.0083 g/kg bw/day, and at a 97.5th percentile consumption was 0.058 g/kg bw/day.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentimans Ginger Beer</td>
<td>Drink</td>
<td>Fermented Ginger Root Extract (Water, Glucose Syrup, Ginger Root, Pear Juice Concentrate, Yeast); Natural Flavourings (Ginger, Lemon, Capsicum)</td>
</tr>
<tr>
<td>Cawston Press Apple &amp; Ginger Juice</td>
<td>Juice</td>
<td>1% Ginger Extract</td>
</tr>
<tr>
<td>Pukka Lemon Ginger &amp; Manuka Tea</td>
<td>Tea</td>
<td>Ginger Root (32%)</td>
</tr>
<tr>
<td>Twinings Spiced Ginger Tea</td>
<td>Tea</td>
<td>Ginger Root* (70%), Liquorice Root* (15%), Cinnamon* (10%), Cloves* (5%)</td>
</tr>
<tr>
<td>No.1 Kombucha Ginger &amp; Turmeric</td>
<td>Tea drink</td>
<td>Kombucha (Filtered Water, Cane Sugar*, Green Tea*, Live Kombucha Cultures), Ginger Juice* (1.5%), Ginger* (0.14%), Turmeric* (0.14%), Black Pepper*</td>
</tr>
<tr>
<td>Teapigs Lemon &amp; Ginger Tea Bags</td>
<td>Tea</td>
<td>Ginger (65%), Lemongrass, Lemon Peel (5%), Liquorice Root</td>
</tr>
<tr>
<td>MOJU Ginger Juice Shot 60ml</td>
<td>Juice</td>
<td>17.2g fresh ginger root*. Apple, Ginger Root (25%), Lemon, Antioxidant: Ascorbic Acid</td>
</tr>
<tr>
<td>Innocent Shots Ginger Kick, Kicking Ginger &amp; Spicy Turmeric 100ml</td>
<td>Juice shot</td>
<td>Apple Juice (54%), Carrot Juice (15%), Ginger Juice (10%), Red Pepper Juice, Lemon Juice, Orange Juice, Jalapeño Pepper Juice, Turmeric Juice (0.2%), Vitamin D</td>
</tr>
<tr>
<td>Plenish Organic Ginger Immunity Juice Shot</td>
<td>Juice shot</td>
<td>Apple, Ginger (20%), Lemon, Apple Cider Vinegar (7%), Acerola Cherry Powder</td>
</tr>
<tr>
<td>Lo Bros Organic Kombucha Gut Shot Ginger</td>
<td>Juice shot</td>
<td>Carrot Juice* (30%), Orange Juice*, Ginger Juice* (25%), Kombucha (14%) (Filtered Water, Kombucha Culture*, Green Tea*, Oolong Tea*, Raw Sugar*), Lemon Juice Concentrate*, Living Cultures</td>
</tr>
<tr>
<td>Belvoir Ginger Beer</td>
<td>Drink</td>
<td>Carbonated Spring Water, Sugar, Lemon Juice from Concentrate, Fresh Root Ginger Infusion 2%, Pressed Ginger Juice, Ginger Extracts, Lemon Extract, Capsicum Extract</td>
</tr>
<tr>
<td>Grace Tropical Rhythms Sorrell Ginger</td>
<td>Drink</td>
<td>Water, Sorrel Cordial (Water, Sugar, Sorrel Flower (3%), Acid: Citric Acid), Rum Flavouring, Natural Sorrel Powder (0.13%), Ginger Emulsion (Water, Ginger Flavouring (0.06%), Acid: Citric Acid, Capsicum, Stabilisers: Acacia Gum, Ester Gum), Colour: E129</td>
</tr>
</tbody>
</table>
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

Table 5: Estimated chronic consumption for ginger in women aged 16 – 49 years old (Bates et al., 2014; 2016; Roberts et al., 2018)

<table>
<thead>
<tr>
<th>Consumers (n)</th>
<th>Chronic consumption*</th>
<th>Respondents in population group (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (g/kg bw/day)</td>
<td>97.5th Percentile (g/kg bw/day)</td>
</tr>
<tr>
<td>1308</td>
<td>0.0083</td>
<td>0.058</td>
</tr>
</tbody>
</table>

*Rounded to 2 s.f.

69. Table 5 indicates the contribution of ginger to the diet of women aged 16-49 years is low, therefore, the main contributor to exposure for some could be from supplement use. This may vary however according to country of origin. For example, ginger is used more and in larger quantities in foods in Asian, African and Caribbean communities.

70. The NDNS does not provide data for pregnant women, therefore there would be uncertainty as to whether this give an accurate reflection of exposure during pregnancy, especially in women who will use ginger drinks and teas or foods such as ginger biscuits to alleviate symptoms of pregnancy associated sickness.

Risk characterisation

71. There is a high uncertainty regarding the risk of consuming ginger drinks and particularly, concentrated ginger ‘shots’, which can contain as much as 27 g of raw, pressed ginger root per serving. Some marketed supplements provide limited composition information, which adds further uncertainty of the exact exposure to the various components of ginger. It is considered likely that in addition to exposure from food and the use of supplements, people may consume ginger in tea or juice form to alleviate nausea and vomiting or symptoms of illnesses such as colds, potentially increasing risk.

72. Based on the available data, ginger showed some mutagenicity in TA 100, TA 1535, and T 98 strains, but this is low compared with established mutagens. Ginger is not shown to be mutagenic in vivo. Ginger showed no signs of acute or sub-acute toxicity in vivo at maximum levels of 5000 mg/kg bw, but studies show it may affect serum ALT and AST levels at doses above 200 mg/kg. From the available studies it appears that ginger exposure could affect hormonal levels in animals thus interfering with reproduction, fertility and resulting in early embryonic loss. Furthermore, there is indication in utero exposure or exposure to ginger during breastfeeding indirectly affected hormonal levels and spermatogenesis in male animals.

73. It is not possible to fully characterise the risks associated with ginger use in pregnancy, due to the lack of safety data available and the varied study results to date. It has been considered that these varied results are attributed to the volatility of
the principle compounds of ginger commonly reviewed - gingerols and shogaols. There is currently limited toxicological information available for the use of ginger during pregnancy. Among the variety of ginger supplements commercially available, there is a large variability in their composition, which also adds uncertainty regarding their use during pregnancy.

Conclusions

74. Ginger (Zingiber officinale) is the rhizome of the ginger plant, originating from in Southeast Asia. Ginger is commonly used as a spice and flavouring in many countries around the world and is increasingly growing in popularity as a natural remedy due to its purported immune system-boosting properties and also for motion sickness and post-operative nausea and vomiting.

75. Ginger supplements are regarded as a “safe” by people looking for a natural alternative for the relief of morning sickness. Some adverse effects have been reported however, few specific safety studies have been carried out in this area.

76. Several ginger supplements are commercially available, ranging from dried root in capsule form to tincture form, all with varying amounts of ginger. In addition to this, concentrated ginger shots, containing large amounts of pressed ginger, are increasingly becoming popular. The variability in the composition of these supplements adds uncertainty on the amount of ginger actually being consumed.

77. The lack of safety and toxicological information available on ginger use in pregnancy make it difficult to fully characterise the risks. From the available studies it appears that ginger exposure could affect hormonal levels in female animals thus interfering with reproduction, fertility and resulting in early embryonic loss. Furthermore, there is indication that in utero exposure or exposure to ginger during breastfeeding indirectly affected hormonal levels and spermatogenesis in male animals. These are indications based on limited studies and although some authors have speculated on the mode of action of ginger, it has not been fully elucidated. Human epidemiological studies have not reported comparable effects and the effects of in utero exposure to ginger in humans are unknown.
Questions for the committee

Members are asked to comment on

a) The effects of ginger in animal studies
b) The effects of ginger in humans?
c) Based on the available information, is the Committee able to identify a point of departure to be used in the risk assessment of ginger?
d) Any other comments on this paper.

Secretariat
April 2021
Abbreviations

μg/kg bw/d - Micrograms per kilogram bodyweight per day
AA - arachidonic acid
ADMET - Absorption, distribution, metabolism, excretion, and toxicity
ADI - Acceptable daily intake
ADP - adenosine diphosphate
ALT - Alanine Aminotransferase
AM - Acetoxymethyl
ASA - Acetylsalicylic acid
AST - Aspartate Aminotransferase
BGL - Blood glucose level
CCB - Ca\(^{2+}\) channel-blocking
COT - Committee on Toxicity
CYP - Cytochrome P450
EFSA - Scientific Committee on Food and the European Food Safety Authority
EMA - European Medicines Agency
GCE - Ginger crude extract
GRAS - Generally recognised as safe
HBBGV - health-based guidance values
INR - International normalized ratio
L-NAME - N\(_{\omega}\)-nitro-L-arginine methyl ester hydrochloride
mg - Milligram
mg/kg bw/d - Milligrams per kilogram bodyweight per day
MHRA - Medicines and Healthcare Products Regulatory Agency
NDNS - The National Diet and Nutrition Survey
PE - Phenylephrine
PGE\(_{2}\) - Prostaglandin-E\(_{2}\)
PTT - Partial thromboplastin time
SACN - Scientific Advisory Committee on Nutrition
STZ - Streptozotocin
TBX\(_{2}\) - Thromboxane-B\(_{2}\)
UKTIS - UK Teratology Information Service
References


AlAskar, A; Shaheen, NA; Khan, AH; AlGhasham, N; Mendoza, MA; Matar, DB; Gmati, G; AlJeraisy, M; AlSuhaibani, A: (2020). Volume 20, 100316. Effect of daily ginger consumption on platelet aggregation.


Holst, L; Wright, D; Haavik, S; Nordeng, H. (2011). Midwifery, Vol 27, Iss 1, 80-86. Safety and efficacy of herbal remedies in obstetrics-review and clinical implications


Kaygusuz, M; Gümüştakım, R.S; Kuş, C; İpek, S; Tok, A. (2021). TCM use in pregnant women and nursing mothers: *A study from Turkey, Complementary Therapies in Clinical Practice* Volume 42, 2021, 101300, ISSN 1744-3881,


Liao, YR; Leu, YL; Chan, YY; Kuo, PC; Wu, TS. (2012). Anti-Platelet Aggregation and Vasorelaxing Effects of the Constituents of the Rhizomes of Zingiber officinale, *Molecules* 17, no. 8: 8928-8937.


Smith, C; Crowther, C; Willson, K; Hotham, N; McMillian, V. (2004). A Randomized Controlled Trial of Ginger to Treat Nausea and Vomiting in Pregnancy. Obstetrics and Gynecology. 103. 639-45. 10.1097/01.AOG.0000118307.19798.ec.


Weidner, MS; Sigwart,K (2001) Investigation of the teratogenic potential of a Zingiber officinale extract in the rat. Reproductive Toxicology, Volume 15, Issue 1, 2000, 75-80,


Yeh, H-Y; Chuang, C-H; Chen, H-C; Wan, C-J; Chen, T-L; Lin, L-Y (2014). Bioactive components analysis of two various gingers (Zingiber officinale Roscoe) and
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

**Antioxidant effect of ginger extracts.** *LWT - Food Science and Technology*, Vol 55, 1, 329-334.


**Secretariat**

**October 2021**
Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment

Meeting of the Committee at 10:00 on 4th May 2021 on Microsoft Teams

Item 10: The potential effects of ginger and ginger supplements during pregnancy and lactation (TOX/2021/26)

1. Dr Stella Cochrane declared that Unilever manufactures teas containing ginger. No other interests were declared.

2. As part of the work on the maternal diet, the Committee considered the use of dietary supplements during pregnancy. A discussion paper (TOX/2020/51) was presented reviewing the commonly used dietary supplements used during pregnancy. These were supplements that were not officially recommended by the relevant authorities, but which were promoted by anecdotal evidence and unofficial sources as having various purported benefits.

3. The review was confined to herbal dietary supplements which would be regulated under food law and which would not be considered to be traditional herbal medicines which are the responsibility of the Medicines and Healthcare Products Regulatory Agency (MHRA). Following this review, the COT agreed ginger required further investigation, noting that human, animal and in vitro data were available.

4. Paper TOX/2021/26 reviewed the available data on toxicity to the mother, effects on the development of the fetus or embryo, and possible interactions with drugs as well as data on potential exposure.

5. Regarding the in vitro data, it was noted that the Inhibitory Concentration (IC)\textsubscript{50} values collated were based on a small amount of data, from only 5 different cell lines.

6. The animal studies reported nothing conclusive in either males or females. It was noted that a study by Hosseini et al (2015)\textsuperscript{5} reported an increase in testosterone in F1 generation males, leading to a decrease in FSH + LH, which would be expected with an increase in testosterone.

7. Members noted that associations with haemorrhagic effects were reported following exposure to ginger, though these were not conclusive. A study by

\textsuperscript{5} Hosseini, E; Jahandidea, A; Mehrabani, D. (2015). Effect of alcoholic extract of Ginger during fetal life and breastfeeding on serum level of testosterone, LH, FSH and spermatogenic cells line in male mature offspring rats. Journal of Gorgan University of Medical Sciences. 17. 29-34.
ElMazoudy and Attia (2018)\(^6\) linked follicular failure to haemorrhagic effects. It was noted that this might be worth further investigating. However, it was also noted that other factors could be contributing to the results observed.

8. The results of studies in pregnant women were also varied and the overall findings inconclusive. There were reports of an increase in spontaneous abortion, but also some contradictory studies. There were no reported effects of defects post-partum.

9. Members questioned what the mode of action for the purported beneficial effects of ginger on nausea might be. It was suggested that ginger might decrease prostaglandin levels, which were linked to nausea. Further studies would be needed to determine if this effect was linked to early termination of pregnancy.

10. The variability of composition for the supplements and extracts compared to food was noted. It was difficult to compare exposure from supplements with that from diet. It would be better to separate diet from concentrates and extracts to clarify this.

11. It was also noted that it was difficult to compare studies, due to the variability of substrates used and the possible presence of environmental contaminants where the natural root had been used.

12. It was noted that contrary to the stated findings, the paper by Willets et al. (2003)\(^7\) did not show strong evidence of an effect on spontaneous abortion. The Committee considered that this needed more detailed consideration.

13. The exposure levels from food were very low compared to those used experimentally, but when supplementation was taken into account, exposure levels were closer to those used in the reported studies. Background levels of ginger in the diet were expected to be much less than those in supplements or highly concentrated drinks. Assumptions would have to be to made on how many of products such as ginger shots were consumed per day. The Committee noted that, as it is commonly understood that ginger suppresses morning sickness, it could not be ruled out that pregnant women would be using the supplements in this way. In terms of exposure, diet plus supplements would need to be considered as well as diet plus shots depending on the exposure period of concern.

14. It was noted that the general public would assume that ginger supplements and shots would be safe. Members agreed that it should be clarified that, whilst ginger consumption in the diet was not considered to be of concern since there was a history of safe use, problems could arise from consumption of products such as the various forms of supplements and that should be the focus of the risk assessment.

---


15. The amount of human evidence is limited, so this would need to be reflected in any risk communication.

16. Ginger was reported to have antiplatelet activity, with some studies reporting effects in animals at doses of 500 mg/kg bw. This further highlighted the need to differentiate exposure from the normal diet to that from supplements.

17. Human data showed possible interactions with medicines. A point of departure for this effect was difficult to determine, however, an estimated level of 100 mg/kg was suggested from animal studies.

18. It was noted that some of the toxicity observed varied according to the nature of extraction solvent - organic solvent extracts exhibited more toxicity than aqueous extracts, which presumably indicates extraction of differentially toxic compounds. Hence, studies of individual extracts might not give the whole picture of the uncertainties involved.

19. The best estimate of a point of departure from available animal studies was around 50-100 mg/kg based on the reproductive studies. The Committee suggested looking at the animal data in closer detail to determine the point of departure (NOAEL), followed by calculating the potential exposure to supplements to determine whether there was cause for concern.

20. It was also noted that any characterisation data of the material used in supplements would be important information, since the products were very variable.

Overall, it was concluded that there was limited data. The human data presented were not strongly indicative of any toxicological concern but there were some indications of possible effects and a lot of uncertainties. Ginger did not appear to be systemically toxic but did appear to have reprotoxic effects at high supplemental doses.

Secretariat
October 2021
Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment

The attached literature studies have been added for reference.


These have not been made publicly available for reasons of copyright.
Committee on toxicity of chemicals in food, Consumer products and the environment

Ginger content in ginger drinks, shots and supplements

Table 1: Chronic and acute consumption of ginger in women of childbearing age (16 - 49 years)

<table>
<thead>
<tr>
<th>Age group</th>
<th>Number of consumers</th>
<th>Mean chronic consumption (g/person/day)</th>
<th>97.5th Percentile chronic consumption (g/person/day)</th>
<th>Mean chronic consumption (g/kg bw/day)</th>
<th>97.5th Percentile chronic consumption (g/kg bw/day)</th>
<th>Mean Acute consumption (g/person/day)</th>
<th>97.5th Percentile Acute consumption (g/person/day)</th>
<th>Mean Acute consumption (g/kg bw/day)</th>
<th>97.5th Percentile Acute consumption (g/kg bw/day)</th>
<th>Number of respondents in population group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women 16 - 49 years</td>
<td>1308</td>
<td>0.55</td>
<td>3.4</td>
<td>0.0083</td>
<td>0.058</td>
<td>1.7</td>
<td>11</td>
<td>--</td>
<td>0.026</td>
<td>0.16</td>
</tr>
</tbody>
</table>
Table 2: Ginger content in shots, teas and other drinks

<table>
<thead>
<tr>
<th>Product</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Shots</strong></td>
<td></td>
</tr>
<tr>
<td>Ginger Shot</td>
<td>Pret A Manger</td>
</tr>
<tr>
<td>Innocent Shots Ginger Kick, Kicking Ginger &amp; Spicy Turmeric 100ml</td>
<td>Contains 10% ginger juice in 100 ml shot, equivalent to 10 g fresh ginger</td>
</tr>
<tr>
<td>Hot Shot</td>
<td>Pret A Manger</td>
</tr>
<tr>
<td>James White Drinks Organic Xtra Ginger Zinger Shot 70ml</td>
<td>Contains 26% organic ginger juice in 70 ml, equivalent to 18.2 g fresh ginger</td>
</tr>
<tr>
<td>James White Drinks Organic Xtra Ginger Zinger Shot</td>
<td>Contains 40% organic ginger juice in 70 ml, equivalent to 28 g of fresh ginger</td>
</tr>
<tr>
<td>MOJU Ginger Shots (12x60ml)</td>
<td>Contains 17.2 g of ginger in a 60 ml shot</td>
</tr>
<tr>
<td>BumbleZest Ginger Turmeric Drink</td>
<td>Contains 16% ginger juice in 60 ml shot, equivalent to 9.6 g of fresh ginger</td>
</tr>
<tr>
<td><strong>Teas</strong></td>
<td></td>
</tr>
<tr>
<td>Myrtle &amp; Maude - Morning Sickness Herbal Tea - Peppermint &amp; Ginger for Nausea Relief</td>
<td>Contains 25% ginger in each tea bag. Assuming that each bag is approximately 2 g, they will contain 0.5 g of dried ginger</td>
</tr>
<tr>
<td>Pukka Lemon, Ginger and Manuka Honey 20 Herbal Tea Sachets 40g</td>
<td>Each tea bag contains ginger root 32%. Assuming each bag is 2 g, they will contain 0.64 g of dried ginger</td>
</tr>
<tr>
<td>Twinings Lemon &amp; Ginger 20 Tea Bags</td>
<td>Each tea bag contains 37% ginger root. Assuming each bag is 2 g, they will contain 0.74 g of dried ginger</td>
</tr>
<tr>
<td>Pukka Organic Ginger, Galangal &amp; Golden Turmeric Tea Bags</td>
<td>Contains 52% ginger root. For a 2 g tea bag, this is equivalent to 1 g of dried ginger</td>
</tr>
<tr>
<td>Twinings Spiced Ginger 20 Tea Bags</td>
<td>Contains 70% ginger root. For a 2 g tea bag, this is equivalent to 1.4 g of dried ginger root</td>
</tr>
<tr>
<td>Lemon &amp; Ginger</td>
<td>Herbal Tea</td>
</tr>
<tr>
<td><strong>Other drinks</strong></td>
<td></td>
</tr>
<tr>
<td>Ginger Kombucha</td>
<td>Pret A Manger</td>
</tr>
<tr>
<td>Belvoir Fruit Farms Ginger Cordial</td>
<td>Contains 11% fresh root ginger infusion and 2% pressed ginger juice in a 500 ml product. This is equivalent to 65 g fresh ginger and 32.5 g in a 250 ml serving</td>
</tr>
<tr>
<td>Pure Pret Sparkling Ginger Beer</td>
<td>Pret A Manger</td>
</tr>
</tbody>
</table>

Please note the different forms of ginger (i.e. gingerols, ginger extract, dried ginger root, fresh ginger) which may not be directly comparable.
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

**Table 3**: Consumption of ginger from supplements

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Maternal supplement ?^</th>
<th>Form of ginger</th>
<th>Recommend ed dose per person/day</th>
<th>Daily Consumption (g/kg bw)*</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seven Seas Pregnancy - 28 tablets</strong></td>
<td>Yes</td>
<td>Ginger extract 10 mg</td>
<td>0.010 g</td>
<td>0.00014</td>
<td></td>
</tr>
<tr>
<td>**Boots Pregnancy Essential Vitamins</td>
<td>90 Tablets**</td>
<td>Yes Ginger root extract 58.5 mg</td>
<td>0.059 g</td>
<td>0.00084</td>
<td></td>
</tr>
<tr>
<td>**Boots Naturals Ginger</td>
<td>60 Tablets**</td>
<td>No</td>
<td>Dried ginger root 1.2 g</td>
<td>1.2 g</td>
<td>0.017</td>
</tr>
<tr>
<td><strong>Boots Pharmaceuticals DIGESTION SUPPORT TRAVEL with added Ginger 30 Capsules</strong></td>
<td>No</td>
<td>Ginger Root Extract to 345 mg and Ginger root-750 mg</td>
<td>0.35 g extract + 0.75 g ginger root</td>
<td>0.005 + 0.011</td>
<td></td>
</tr>
<tr>
<td>**Good n Natural Ginger Root Capsules 550mg</td>
<td>Holland &amp; Barrett**</td>
<td>No</td>
<td>Ginger root</td>
<td>1.1 g</td>
<td>0.016</td>
</tr>
<tr>
<td><strong>Ginger 3000mg Tablets – Supplemented</strong></td>
<td>No</td>
<td>Ginger extract</td>
<td>6.0 g</td>
<td>0.085</td>
<td></td>
</tr>
<tr>
<td>Product</td>
<td>Available as?</td>
<td>Form of Ginger</td>
<td>Consumption per body weight</td>
<td>Concentration</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>-------</td>
</tr>
<tr>
<td>Solgar Ginger Root Extract (60 Veg Caps)</td>
<td>No</td>
<td>Ginger root powder + Ginger root extract</td>
<td>0.15 g + 0.30 g</td>
<td>0.0021 + 0.0043</td>
<td></td>
</tr>
<tr>
<td><strong>GINGER 250mg 120 Vegetarian Capsules by BIOVEA</strong></td>
<td>No</td>
<td>Ginger root</td>
<td>0.75 g</td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td>Jarrow Formulas Ginger (100 Capsules)</td>
<td>No</td>
<td>Ginger root concentrate</td>
<td>1.5g</td>
<td>0.021</td>
<td></td>
</tr>
<tr>
<td>**High Strength Ginger Root Capsules</td>
<td>Nature’s Best**</td>
<td>No</td>
<td>24mg gingerols equivalent to 14.4g fresh ginger</td>
<td>14.4g</td>
<td>0.20</td>
</tr>
<tr>
<td>Ginger 12000mg x 120 Tablets</td>
<td>Nausea - Stomach Settle - Aids Digestion</td>
<td>Neulife Health &amp; Fitness</td>
<td>No</td>
<td>Ginger extract 600mg equivalent to 12g fresh ginger-</td>
<td>24g</td>
</tr>
<tr>
<td><strong>Lifeplan Ginger Root 1000mg 90 Tablets</strong></td>
<td>No</td>
<td>Ginger Extract (equiv. herb powder 1000mg) 50mg</td>
<td>2g</td>
<td>0.028</td>
<td>2 tablets/d day</td>
</tr>
</tbody>
</table>

*Consumption per body weight based on recommended dose rounded to 2 significant figures
is calculated from the daily recommended intake and the average body weight of women aged 16-49 years (70.3kg)

^Indicates whether the supplement is marketed specifically to pregnant or breastfeeding women
Please note the different forms of ginger (i.e. gingerols, ginger extract, dried ginger root, fresh ginger) which may not be directly comparable.
This is a background paper for discussion. It does not reflect the final views of the Committee and should not be cited.

References